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Abstract 
 
Multiple primary malignant tumours (MPMT) are an indicator of potential inherited 
cancer susceptibility and occur at appreciable frequency among unselected cancer 
patients and, particularly, among referrals to cancer genetics services. However, 
there is little information on the clinical genetic evaluation of cohorts of MPMT 
patients representing a variety of tumour types. A referral based case series was 
ascertained and is described. Service-based molecular genetic testing had 
demonstrated a pathogenic germline variant in a cancer predisposition gene in 
less than a quarter of referrals. To assess for evidence of unidentified variants in 
those who tested negative, comparisons were made with those who tested 
positive, revealing considerable overlap between the two groups with respect to 
clinical characteristics indicative of an inherited cancer syndrome. A subset of 
unexplained MPMT cases was subsequently analysed for mutations in TP53, 
PTEN and CDKN2B but none were detected. MPMT individuals may receive 
negative genetic test results for a number of reasons, which are discussed. They 
include referral bias and MPMT cases from a population based registry were also 
analysed and compared with the referral based series. The increasing application 
of next generation sequencing techniques in clinical services is likely to address 
many of these issues.  
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List of definitions  
Variant – A change in the sequence or structure of a gene as compared to a 
reference dataset. Does not imply functional effect or pathogenicity. 
Mutation – As per variant, though generally taken in the field of Clinical Genetics 
to imply that the change is deleterious and/or pathogenic. Also refers to the 
process of genetic changes occurring.  
Missense – A genetic change resulting in the substitution of one amino acid for 
another in a gene’s protein product.  
Non-sense – A single nucleotide genetic change that results in the generation of a 
stop codon and a truncated protein product.  
Frameshift – A genetic change resulting in loss of the translational reading frame 
of a gene with consequent changes to amino acids incorporated through 
translation downstream of the change. Frequently results in a premature stop 
codon and a truncated protein product.  
Dominant inheritance - A condition where mono-allelic mutations are sufficient 
for the phenotype to manifest. 
Recessively inherited condition – A condition where bi-allelic mutations are 
necessary for the phenotype to manifest. 
Constitutional variant/mutation – A variant/mutation that exists in a significant 
proportion of cells in an individual.  
Germline variant/mutation – A variant/mutation that is present in germ cells. 
Inheritance of such a variant/mutation by offspring results in a constitutional 
variant/mutation in that individual. Genetic testing of blood samples is often 
interpreted as testing a tissue that is representative of cells present at conception 
and identified variants/mutations may be referred to as germline.  
De novo mutation – A constitutional mutation that occurred in the parental 
gamete or post conception and is therefore not present in either parent. 
Cancer predisposition gene – A gene where constitutional deleterious mutations 
confer predisposition to developing cancer. This may be through inheritance from 
a parent or a post conception event.   
Penetrance – The degree to which the phenotype associated with mutations 
manifests in mutation carriers. A low penetrance mutation may lead to no 
observable phenotypic effect whereas a high penetrance mutation leads to an 
associated phenotype in most or all cases.    
Amplicon – A genomic region amplified by an individual polymerase chain 
reaction primer pair.  
Next generation sequencing – A group of techniques that utilise simultaneous 
sequencing of large numbers of nucleic acid sequences. Resulting sequence 
readouts are computationally aligned to a reference sequence for interpretation. 
The sequenced nucleic acids vary according to technique and can include 
effectively all genomic regions (whole genome sequencing), all protein coding 
regions of the genome (whole exome sequencing) or a selected group of genes 
(gene panel).  
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Much of Chapter 1 Section 4, the majority of Chapters two and three and a 
proportion of Chapter five have previously been published1.  
 
Chapter 1 – Introduction and aims 
 
Section 1: Genetic predisposition to cancer 
 
Cancer as a genetic disease  
The concept of the cancer as a clonal expansion of cells that have undergone 
genomic changes conferring malignant properties is now broadly accepted. The 
development and testing of this hypothesis has been a process guided by the 
application of new technologies, in this case to analyse cellular genetic material at 
increasing resolution and in increasing quantity. Advances in genomic techniques 
are allowing the next step in this process to take place.  
 
In the nineteenth century, microscopic analysis led to the observation that 
chromosome aberrations can occur in malignant cells2. Boveri was one of the first 
to put forward the idea that such aberrations might be a key causative factor in 
tumourigenesis. By studying abnormal mitoses in sea urchin embryos, he 
hypothesized that abnormal cellular properties, including malignancy, were 
conferred by an unbalanced chromosome complement. His work included 
assertions regarding “inhibiting chromosomes” i.e. those that normally act to 
suppress cell division and “stimulatory chromosomes,” which change a cell’s 
relationship with its external environment to encourage a proliferative state. These  
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ideas were remarkably prophetic of the proto-oncogenes and tumour suppressor 
genes (see below) that later became familiar3. It was not until the 1960’s that a 
specific chromosomal abnormality was associated with a particular tumour when 
the Philadelphia chromosome (resulting from a translocation of chromosomes 9 
and 22) was identified as present in all studied chronic myeloid leukemia patient 
samples4. 
 
Abnormal chromosomes may be a result of the genomic instability caused by 
tumourigenic processes but may also, as in the case of the Philadelphia 
chromosome, be important initiating events. With the development of gene 
sequencing techniques it became possible to study the molecular consequences 
of such events at the gene level and also define causative genetic abnormalities, 
not visible by chromosome analysis, that occur at the nucleotide level.  
 
Oncogenes, tumour suppressor genes and cancer predisposition 
A crucial step in understanding how genetic changes in tumours lead to cancer 
was the development of the concept of the oncogene, a gene that has undergone 
change rendering it as contributory to tumour development. These changes result 
in enhanced or altered function of a given oncogene’s normal counterpart, termed 
a proto-oncogene. Proto-oncogenes are involved in a variety of cellular processes 
pertinent to cell growth/proliferation including cell cycle regulation and growth 
signalling. Oncogenes were initially identified through analysis of tumour cells 
whose malignant properties had been induced by a retrovirus. The tumorigenic 
potential of such viruses was found to be due to one component gene of the virus, 
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designated the oncogene5. Further research revealed that orthologues of the viral 
oncogenes were present in normal cells and were labelled proto-oncogenes5.  
 
The discovery of the other main class of gene significant in the development of 
cancer, the tumour suppressor gene (TSG), was to provide the key step in the 
understanding of inherited tumours. In its normal state, a TSG often functions to 
inhibit cell proliferation but loss of function mutations compromise this role and 
promote tumourigenesis. In some cases, inactivation of a TSG directly leads to 
cellular attributes that favour malignant transformation but in other cases (e.g. 
inactivation of a TSG involved in DNA repair mechanisms with resulting failure to 
repair mutations in other TSGs or proto-oncogene) the pro-tumourigenic process 
is indirect.  
 
Whilst some genetic changes appear particularly important in conferring tumour 
defining properties to cells, a cell’s transition from normal to malignant is a multi-
step process. A source of much debate, often based on epidemiological evidence, 
has been how many changes are required for the completion of this process. Work 
by Nordling observed cancer mortality correlating with age and estimated that, on 
average, six mutational events in a given cell were required for a cancer to occur6. 
The work only studied certain cancer types and observed that many malignancies 
did not conform to this model.  
 
Seminal work by Knudson et al suggested that at least one cancer type 
(retinoblastoma, a rare childhood cancer of the eye) could be caused by two 
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mutational events affecting different alleles at the same locus. By observing 
tumour frequencies in presumed inherited and sporadic cases and estimating the 
mutation rate at the relevant theoretical locus, a model was proposed whereby 
those who inherit a mutated TSG allele from a parent require only a single 
mutation event (“hit”) in the other allele for a tumour to be initiated. Sporadic 
cases, on the other hand, must acquire both hits post conception7 (see Figure 1). 
This model explains the very high risk of retinoblastoma in individuals with the 
familial form where bilateral tumours occur, and the later onset unilateral tumours 
in sporadic cases.  
 
The causative genetic factor in familial retinoblastoma is a constitutional aberration 
affecting the RB1 gene. This gene was identified through analysis of 
retinoblastomas with Knudson’s two hit hypothesis in mind. There was previous 
evidence that a section of chromosome 13 was the area affected by the 
hypothesized second hit. Some retinoblastoma patients had been shown to 
harbour a constitutional deletion in this area8 and acquired loss or partial deletion 
of this region of chromosome 13 had been shown in retinoblastoma tumour cells9. 
Identification of the RB1 gene within the target region was followed by 
demonstrating that inherited cases had an inactivating constitutional mutation and 
a second hit in the tumour cells, whereas tumours from non-inherited sporadic 
cases harboured inactivating hits in both RB1 alleles that were not present in the 
patient’s normal cells (so both events were somatic)10. 
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Knudson’s work and the subsequent identification of the RB1 tumour suppressor 
gene10 was a key step in the development of inherited cancer genetics. Apart from 
highlighting the role of TSGs in cancer pathogenesis, it demonstrated that 
inherited constitutional mutations causing cancer predisposition were identifiable 
through the study of affected families and that the genes affected by them can also 
be implicated in sporadic tumours.  
 
Figure 1 – Knudson’s two hit model 
 
 
The discovery of RB1 prompted an extensive and ongoing search for further 
cancer predisposition genes (CPGs) that has yielded findings of relevance to 
affected individuals and also tumours occurring outside of the inherited context. 
Identified genes may not conform to the two hit TSG model and a number of 
constitutionally activated proto-oncogenes have been found to be associated with 
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familial cancers (e.g. those in the RET gene leading to Multiple Endocrine 
Neoplasia Type 211,12). The search for inherited cancer genes has focused on 
individuals with clinical characteristics of inherited cancer predisposition (e.g. 
family history of cancer, multiple tumours, phenotypic markers and young age at 
diagnosis) but advances in genetic technology are providing the means for large 
scale mutation screening in individuals without classical features of an inherited 
cancer syndrome. 
 
Identifying cancer predisposition genes 
A variety of approaches have been employed to identify CPGs including candidate 
gene analysis, positional cloning, positional-candidate gene analysis and 
comprehensive sequencing with next generation sequencing (NGS) technologies. 
Earlier studies concentrated on large families with high penetrance cancer 
phenotypes and used genetic linkage studies to identify regions that segregated 
with cancer predisposition in the family. In some cases (e.g. RB1) the putative 
localisation of the cancer predisposition gene was supported by deletion/allele loss 
analysis in tumour material. Having defined an interval of interest, all genes within 
the region were then sequenced until the gene containing germline mutations was 
identified. As illustrated by RB1, some CPGs are targets for somatic mutations in 
sporadic tumours. A typical candidate gene approach would be to take a gene 
known to be somatically mutated in a sporadic cancer and test whether inherited 
cases harbour constitutional mutations in that gene (e.g. PBRM1 mutations in 
familial renal cell carcinoma13). A positional-candidate gene approach has been 
used widely, particularly since the advent of detailed maps of the human genome, 
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as following the identification of a candidate region of linkage, the genes within the 
target interval can be prioritised according to their relevance to cancer and 
analysed accordingly.  
 
High throughput NGS techniques utilise massively parallel sequencing of short 
genomic sequences that are computationally aligned to a reference sequence to 
identify variants in the studied sample. They have enabled sequencing of whole 
genomes, the coding regions in their entirety (whole exomes) or a selected series 
of genes (through targeted amplification and capture of genomic regions of interest 
in the latter two techniques) in cases where genetic linkage studies are not 
possible, for example if DNA is only available from a single affected family 
member. Although the challenges of correctly interpreting the resulting large 
numbers of rare genetic variants should not be underestimated, these assays 
have greatly facilitated the identification of CPGs in research studies as well as in 
diagnostic laboratories. Their utility is illustrated by the discovery of POT1 as a 
melanoma predisposition gene. POT1 was identified by the application of NGS 
techniques to families where multiple members were affected with this cancer. 
Whole exome or whole genome sequencing was performed in individuals 
belonging to 28 families where two or more melanomas had occurred and where 
there were three or more members available for analysis. This latter criterion 
increased the ability of the study to exclude potentially causative variants that were 
not present in affected cases (or were present in unaffected cases). The large 
number of variants identified through sequencing were filtered using bioinformatic 
techniques to exclude those that were unlikely to be the cause of melanoma. 
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Variants were excluded if they were common and therefore unlikely to explain the 
relatively rare phenomenon of familial melanoma. They were also not retained if 
they were unlikely to affect the function of the corresponding protein product. 320 
genes were found in the families that had variants fitting the above criteria. 
Crucially, only five of these were shared by more than one of the families. Further 
analysis focused on these and demonstrated that the variants in one of them 
(POT1) could be found in further families with familial melanoma and disrupted 
biological function of the gene14. 
 
Methodologies as described above generally begin without a hypothesis in terms 
of which gene may harbour the causative mutation. Initial analysis, particularly for 
NGS approaches, is likely to generate gene lists for further investigation and 
selection of putative causative genes at this stage is aided by candidature 
provided by existing sources of evidence. This might be expression of the gene in 
the organ of interest or involvement of it in a cellular process relevant to cancer 
(e.g. DNA repair). Observation of somatic alterations in a cancer type 
corresponding to that seen in the studied family may also prompt candidature. An 
example of this is the identification of RB1 as illustrated above and the knowledge 
that TP53 was recurrently mutated in many cancer types was helpful in the genetic 
characterisation of Li-Fraumeni syndrome, caused by constitutional mutations in 
that gene15. In recent years, molecular characterisation of tumours has become 
more extensive through cancer genome projects and is likely to further assist with 
identification of CPGs in this way. The cBioportal for example, contains information 
from over 20,000 sampled tumours from various projects16. 
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Risks associated with mutations in cancer predisposition genes 
While NGS technologies and improved candidature have enhanced the rate of 
novel CPG discovery, mutations in many of them have been estimated to cause 
lower cancer risks than some of the earlier discoveries such as APC, VHL and 
TP53. The majority of high risk cancer predisposition genes affecting large 
numbers of families may have been discovered, leaving more recent and future 
discoveries falling into a number of categories according to the risk that mutations 
affecting them confer.  
 
Newly identified high risk genes are more likely to be rare and account for a 
smaller proportion of overall cancer burden. Current sequencing and bioinformatic 
techniques applied to small numbers of families are well placed to identify them. 
Their clinical utility will be significant for affected families and can provide insights 
into non-familial tumours of similar morphology.  
 
Mutations in genes leading to moderate levels of cancer risk are unlikely to cause 
a characteristic cancer in all carrying members of families where they are present. 
Consequently, study designs relying on analysis of variants that are shared 
between affected family members may be less informative. Studies comparing 
variants seen in large series of patients with a particular cancer with a control 
series can reveal significant association of variant with tumour without necessarily 
reflecting a very high risk of that tumour developing. Examples of predisposition 
genes identified in this way include BRIP1 and PALB2, reported to confer a 
relative breast cancer risk of 2 and 2.3 respectively17,18. Interestingly, further 
10 
 
observation of PALB2 mutation carriers has revised this estimated risk to a much 
higher level19. 
 
Identification of the genetic basis of highly penetrant cancer predisposition 
phenotypes can have a major effect on management of affected families (see 
below) but only impact on a small minority of patients with the relevant cancer. 
Genome wide association studies (GWAS) of large cohorts of cancer patients 
have been employed to identify common genetic variants that predispose to 
specific cancers. The identification of such susceptibility alleles can provide 
pointers as to molecular pathways significant to particular tumours but generally 
haven’t been translated into clinical practice because the increased risk associated 
with each variant is small. Ultimately, clinical utility might be provided by identifying 
individuals who harbour multiple low risk variants that combine to put the individual 
at a significantly increased risk. One analysis to assess this potential combined 
risks derived from 77 variants previously associated with breast cancer in GWAS 
to produce a combined risk score. The score was used to stratify over 30,000 
breast cancer cases and controls into quintiles. It was found that in those without a 
family history, the highest scoring quintile had significantly higher lifetime breast 
cancer risk (16.6%) than those in the lowest scoring quintile (5.2%). This 
difference was more pronounced in those with a first degree relative with breast 
cancer (8.6% vs 24.4%)20. Risk estimates at the level of those assigned to the 
higher risk group approach those deemed sufficient for intervention in the cancer 
genetic clinic.  
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Section 2: Clinical utility of cancer predisposition gene analysis 
 
Identification of CPGs through the study of affected individuals and families has 
provided the opportunity to extend genetic analysis to large numbers of 
individuals, often without a family history, who are considered to be at risk of an 
inherited cancer syndrome (e.g. a significant proportion of patients with 
phaeochromocytoma/paraganglioma without a relevant family history have a 
causative constitutional mutation21). This consideration is generally based on 
factors indicative of genetic predisposition and/or a particular syndrome such as 
young ages at diagnosis, multiple tumours and a particular tumour spectrum 
occurring in the family. 
 
The case to perform germline genetic testing may be particularly compelling where 
rarer tumours cluster within the same family as alternative causes are less likely. 
The picture is more ambiguous where common tumours cluster. Such a scenario 
may represent inherited predisposition or be the result of higher population 
incidences of particular tumours leading to occurrence in multiple family members. 
Sporadic tumours that appear consistent with a constitutional genetic cause may 
be termed phenocopies and are more likely to be present where environmental 
factors frequently lead to a particular tumour type. However, there is not a simple 
relationship between how common a specific cancer is and whether it is genetic or 
environmental in origin. An assessment of the proportion of cancer cases 
attributable to 14 common preventable environmental exposures has shown 
relatively low figures for many of the most frequent tumours occurring in the 
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population e.g. breast (26.8%) colorectal cancers (54.4%)22. In many cases, 
clinical genetic testing is able to distinguish between clustering of common 
tumours caused by mutations in CPGs and due to other mechanisms.   
 
Genetic testing is termed diagnostic in an individual who has previously been 
diagnosed with a cancer and where a genetic explanation is sought. Predictive 
testing generally interrogates the genetic status of an unaffected person for a 
causative variant previously identified in a family member, though advances in 
testing technology and knowledge of CPGs is likely to lead to much more 
predictive testing where such a mutation has not been found in a relative. In the 
ideal scenario, results from such analysis can provide accurate risk assessment 
and potentially insight into tumour biology in the tested individual. Clinical utility 
may therefore be derived in a number of ways.  
 
Information as therapy 
Risk information based on genetic test results may enhance management by 
providing patients with a clear explanation for cancers that are often of early onset 
and affect multiple family members. Negative results can provide reassurance but 
often leave open the possibility of unidentified pathogenic variants such that a 
genetic predisposition cannot be definitively excluded. A genetic diagnosis, 
although potentially increasing perceived future cancer risk, often comes with a 
defined spectrum of associated tumours. These specific risks, which can be 
managed, may be preferable to a generalised increased cancer risk that can be 
perceived by the patient prior to testing. A notable exception is Li-Fraumeni 
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syndrome, where the cancer risks are very broad and where there is little clinical 
surveillance currently demonstrated to be of benefit. Uptake of predictive testing 
for this condition however, is broadly similar to other commonly performed 
predictive tests where better management can be offered23. A systematic review of 
psychological outcomes in women with a family history of breast cancer 
undergoing genetic testing found a significant reduction in psychological distress in 
women receiving negative results and little change in those receiving positive 
results24. A study of individuals undergoing predictive testing for BRCA1 or BRCA2 
mutations found that 92% would recommend the process to others in the same 
situation25. Assessment of benefits such as this should be seen in the context of 
testing uptake, which has been shown to be around half of individuals eligible for 
predictive testing in the most commonly seen conditions in the genetics clinic26,27. 
Those not pursuing testing may not have gone on to have an equally positive 
experience.  
 
Individuals consulting clinical services for assessment for a possible predisposition 
syndrome frequently do so in an attempt to provide a genetic diagnosis in the 
family. This gives the opportunity for relatives to predict and manage their risks 
and may be of benefit to the consulting patient even if their own prognosis is poor. 
An assessment of motivations for diagnostic testing in a series of colorectal cancer 
patients undergoing testing showed greater importance placed on this than a 
desire to increase certainty as to whether or not an increased risk of colorectal 
cancer was present in the consultand28. 
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Finally, identification of mutations in CPGs in a potential parent may facilitate 
reproductive decisions or lead to testing for the variant in a foetus in utero (pre-
natal diagnosis (PND)) or pre-implantation embryos resulting from in vitro 
fertilisation (pre-implantation genetic diagnosis (PGD)). Test results can affect 
decisions as to whether to continue a pregnancy or which embryos to select for 
implantation. This is a model largely used in severe (mainly non-cancer) childhood 
onset disorders and is less frequently applied to most cancer predisposition 
syndromes due to their generally later onset and more manageable 
manifestations. However, a number of adult onset cancer syndromes appear on 
the Human Fertilisation and Embryo Authority’s approved list for PGD29 and high 
levels of agreement with PND for Lynch syndrome among individuals at risk of 
Lynch syndrome30 suggest that this may change in future.  
  
Clinical surveillance 
The current mainstay of management following the diagnosis of a cancer 
predisposition syndrome are interventions designed to prevent cancers occurring 
or diagnose them at a more treatable stage. The latter is achieved through regular 
clinical surveillance of at risk tissue. This may be via a number of modalities 
depending on the tissue or syndrome in question and imaging, endoscopic 
examination and biochemical analysis are frequently used. Frequency and age at 
which surveillance investigations are performed are guided by observational 
evidence from series of affected cases. The quality of such guidance is often 
compromised by the rarity of a condition and/or ascertainment biases influencing 
which patients are included in these series. The gold standard of a prospective 
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study of mutation carriers to observe may be difficult to achieve but collaboration 
between centres is likely to lead to more accurate assessments of risks and also 
screening outcomes. The effectiveness of surveillance programmes is currently 
uncertain for most predisposition syndromes. For more common conditions, larger 
cohorts that can be assembled in one or a few centres can provide greater clarity 
on the issue. In Lynch syndrome, a number of studies comparing screened and 
unscreened groups have been published, allowing a systematic review. The 
multiple studies showing reduction in colorectal cancer incidence and related 
mortality in screened (with regular colonoscopy) patients provide convincing 
evidence for the utility of this strategy. In rarer conditions, inference may have to 
be made from less direct sources of information. Von Hippel Lindau disease (VHL) 
is one such condition that predisposes affected individuals to central nervous 
system haemangioblastoma, phaeochromocytoma and renal cell carcinoma. 
Protocols for surveillance are widely used but no prospective follow up data 
comparing screened with unscreened patients exists. However, life expectancy in 
VHL patients has been observed by identifying cases through genetics service and 
cancer registries. Whilst a reduced life expectancy was noted (52.5 years), the 
mean survival increased by 16.3 years in patients diagnosed after 1990 when the 
genetic service registry, and therefore increased systematic surveillance protocols, 
was introduced31.  
 
Surveillance programmes for conditions with diverse tumour risks can lead to the 
proposal of complex screening programmes which may have poor acceptability for 
patients and whose outcomes are difficult to assess. An appealing approach is 
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that of a single modality screening test that can address these issues. A candidate 
for a modality like this is a whole body MRI scan, which is currently being 
investigated in Li-Fraumeni syndrome32. Crucial outcomes will include the rate of 
potentially significant findings and effects of resulting interventions. This is true for 
any screening test but a whole body approach combined with the range of tumour 
risks in Li-Fraumeni syndrome make them particularly pertinent.  
 
Clinical surveillance has more potential to do harm (e.g. through unnecessary 
resulting surgery) where the penetrance of a mutation in a given cancer 
predisposition gene is not high. In Hereditary Leiomyomatosis and Renal Cell 
Carcinoma (HLRCC) caused by FH mutations, only 15-20% of mutation carriers 
develop kidney cancer but of those that do, many are at an advanced stage 
resulting in a poor prognosis33. As well as assessing screening programmes in as 
extensive series as possible therefore, an important area of research is risk 
stratification within inherited cancer syndromes. Stratification might be based on 
the particular variant in the causative gene (see below) or through constitutional 
variants in other genes that may influence cancer risk (modifier genes). 
Alternatively, acceptability, specificity and sensitivity of screening tests might be 
improved for those individuals at low risk by exploiting the phenomena of 
circulating tumour DNA. Identification of specific genetic markers of tumour cell 
origin in a predisposition syndrome such as HLRCC could facilitate an effective 
surveillance programme based on blood sampling. 
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Prophylactic surgery 
In some predisposition syndromes, prophylactic surgery may represent the most 
effective preventative strategy. Utility and uptake of this can depend on a number 
of factors such as level of risk reduction from tissue removal, function (and loss 
thereafter) of the tissue in question and likelihood of complications following the 
procedure. These factors need to be considered against the efficacy of 
surveillance strategies as an alternative. Prophylactic surgery can result in 
dramatic reduction in tumour risk. In hereditary breast and ovarian cancer caused 
by BRCA1 and BRCA2 mutations, bilateral mastectomy is estimated to reduce the 
risk of breast cancer by around 90%34. Similar to surveillance, utility of surgery in 
other syndromes may be more difficult to estimate due to rarity of the condition 
and/or lack of an adequate control (no surgery performed) group with which to 
compare survival rates. In familial adenomatous polyposis, the risk of colorectal 
cancer35 has been estimated at a level sufficient to warrant colectomy in all 
diagnosed cases, leaving a low number of cases with an intact colon for further 
study.  
 
Pharmacological management 
In cancer predisposition syndromes, the benefits of chemo-preventative strategies 
are especially likely to outweigh disadvantages resulting from side effects or 
economic cost. Use of preventative agents may be based on observations relating 
to tumours occurring outside of the familial context. Lower colorectal cancer rates 
in individuals taking long term aspirin36 led to a trial of its use in Lynch syndrome, 
which leads to high risks of that malignancy. A significant reduction in bowel 
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cancer incidence was observed in the trial leading to the recommendation that this 
medication should be discussed with affected individuals37.  
 
Recent years have brought an increasing focus on the use of a patient’s 
constitutional mutation status to guide medical therapy to both treat and prevent 
tumour development. This knowledge can provide insight into the biology of the 
tumour sufficient to prompt clinical trials. Though such therapies are currently 
limited in number, they are a source of wider optimism in cancer predisposition 
syndromes. Strategies generally involve the inhibition of an abnormally 
active/upregulated gene product or cellular pathway as exemplified by the use of 
vismodegib in Gorlin syndrome (basal cell nevus syndrome). This is an autosomal 
dominant condition associated, among a wide range of other features, with 
multiple early onset basal cell carcinomas (BCCs). Study of affected families 
demonstrated that it was caused by mutations in PTCH1, the gene product of 
which performs an inhibitory function in the hedgehog signalling pathway38,39. This 
pathway is a key regulator of cellular development in early life but is abnormally 
active in Gorlin related BCC cells due to a “second hit” in the wild type PTCH1 
allele40. PTCH1 was subsequently shown to be mutated in most sporadic BCCs 
and a trial of vismodegib (an agent previously known to inhibit the hedgehog 
pathway) was shown to be efficacious. Subsequent trials have also shown 
reduction in BCC occurrence in Gorlin patients41. The example illustrates the 
development of therapy based on germline mutation status and also how 
identification of relevant mutations in rare syndromic tumours can inform 
knowledge and treatment of their sporadic counterparts.  
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Notable exceptions to strategies inhibiting an abnormally active/upregulated gene 
product or cellular pathway exist such as the example of poly ADP ribose 
polymerase (PARP) inhibitors in BRCA1/2 related cancers, which disrupt a DNA 
repair mechanism (base excision repair). Tumour cells in BRCA1/2 mutation 
carriers have generally acquired an aberration affecting their BRCA1/2 wild-type 
allele and are therefore deficient in a different repair process (double stranded 
DNA repair by homologous recombination), rendering them susceptible to PARP 
inhibitor induced cell death compared to other cells in the same patient42.  
 
More extensive definition of tumour phenotypes associated with predisposition 
syndromes by improved molecular analysis should continue to yield abnormalities 
targetable by therapeutic agents. Sequencing of breast cancers with whole 
genome sequencing has previously revealed a distinct mutational signature in 
BRCA1 or BRCA2 related cancers that is consistent with the known DNA repair 
deficit in these patients43. Similar work may be rewarding on tumours from patients 
with other syndromes, perhaps where the function of the relevant gene is less well 
characterised. This should provide opportunities for stratification and treatment 
akin to those produced by the study of sporadic cancers. 
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Section 3: Cancer predisposition genes 
 
The number of genes in which constitutional mutation leads to cancer susceptibility 
currently stands in three figures, though defining a CPG is not without difficulties. 
For every gene where mutation carriers have high risks, there are others where 
mutation carriers are more likely to remain unaffected by the cancer/s they are at 
risk from. Many constitutional genetic variants have been associated with 
increased risk of particular cancers through GWAS but the risk conferred by these 
is generally not at a level prompting the management strategies described above. 
A comprehensive review of CPGs was published by Rahman in 2014 and included 
genes where rare mutations confer a doubling of relative risk of cancer and lead to 
5% of carriers being affected with cancer44. At the lower end of these risks, 
however, it is doubtful whether surveillance or prophylactic surgery would be of 
benefit.  
 
Phenotypic effects of mutations in cancer predisposition genes 
CPGs are involved in an array of cellular processes where aberrant function can 
lead to cancer defining phenomena such as genomic instability, disrupted cell 
cycle regulation or increased proliferation. Mutations in these genes can lead to 
phenotypic expression consistent with various models of inheritance seen in high 
penetrance genetic conditions. The majority of associated phenotypes are 
inherited in an autosomal dominant manner, often with unaffected mutation 
carriers seen in the family due to incomplete penetrance. Mutations in a gene 
causing a dominantly inherited syndrome may be embryonically lethal in the rare 
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scenario that one is inherited from both parents. A number of recessive inherited 
cancer syndromes have also been described, most notably colonic polyposis and 
colorectal cancer due to bi-allelic mutations in MUTYH45. There are other intriguing 
examples where the inheritance of a mutation in a CPG has contrasting effects 
depending on whether it is inherited in the mono-allelic or bi-allelic state. This 
might lead to a phenotype differing qualitatively or in terms of severity. 
Heterozygous SDHB mutations cause phaeochromocytoma and paragangliomas46 
whereas the inheritance of a mutation on both chromosomes leads to a 
neurodevelopmental disorder47. The tumour risks in bi-allelic cancer predisposition 
mutations may still be present but often unable to manifest themselves due to 
reduced life expectancy. Mono-allelic ATM mutations are associated with an 
increased risk of breast cancer whereas Ataxia Telangiectasia caused by bi-allelic 
inheritance causes a number of features such as ataxia and haematological 
cancers. However, breast cancer has also been reported in longer surviving 
cases48.  
 
Some inherited cancer syndromes such as Li-Fraumeni syndrome are associated 
with an increased risk of a wide range of cancer types but most conditions are 
currently known to lead to increased risk of a small number of specific tumours. 
Even Li-Fraumeni related cancers are among a set of four core malignancy types 
in 70% of cases49. The reason for this specificity is yet to be elucidated in most 
cases, though biological explanations include the restriction of gene 
expression/action to particular tissues and aberrant cellular mechanisms rendering 
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cells susceptible to further mutation through environmental exposures only 
relevant to particular organs.  
 
 
Some phenotypic specificity may be explained by ascertainment biases influencing 
the study of CPGs and their associated tumour risks. Identification of such genes 
has usually been through the preferential study of families where there are a 
number of occurrences of the same tumour or group of tumours, restricting other 
possible associations. Furthermore, more likely to be studied are those cases 
where the phenotype is more severe e.g. earlier age of tumour diagnosis. The 
identification of novel CPGs in these scenarios is likely to underestimate the range 
of tumours caused by mutations in that gene and overestimate the clinical severity 
of harbouring them. These effects may be exacerbated by the effect of clinical 
criteria to guide access to genetic testing, which appears to have occurred in 
Lynch syndrome. 
 
Lynch syndrome is a cancer predisposition syndrome conferring susceptibility to a 
variety of cancers, primarily colorectal. It is caused by heterozygous mutations in 
mismatch repair genes such as MLH1, MSH2 and MSH6. Colorectal cancer is a 
common condition and clinical criteria have previously been used to identify those 
families likely to have tumours due to Lynch syndrome as opposed to an 
alternative cause. The Amsterdam criteria50 were developed to provide 
consistency of reporting of suspected Lynch syndrome families and require a 
severe family history in order to be fulfilled. The Bethesda criteria51 are designed 
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to prompt the initiation of molecular investigations for Lynch syndrome and 
incorporate a wider range of families while still requiring relatively strong evidence 
of a predisposition syndrome.   
 
Where genetic investigations were/are less available, rationing of analysis is likely 
to be based on such criteria on the basis that those fulfilling them are more likely 
to harbour a causative mutation and represent a more efficient use of resources. 
This may lead to an overestimate of the tumour risks associated with identified 
mismatch repair mutations as those families where their effect is less severe are 
less likely to been eligible for testing. Those who receive testing (and test positive) 
may also have greater risks conferred by other modifying genetic variants and not 
only due to the identified mutation, overestimating its effect. Indeed, earlier studies 
estimated a higher risk of colorectal cancer than has more recently been reported. 
A large 1999 analysis of registry recorded Finnish mutation carriers showed a 
cumulative incidence of colorectal cancer of 82% by age 70, 68 times higher than 
the population from which the cases were drawn52. However, a 2009 assessment 
of mutation carriers identified through genetics clinics and corrected for 
ascertainment bias estimated a lower cumulative incidence of 66% to age 7053. 
 
Expansion of phenotype associated with mutations in a particular gene following 
initial discovery based on a narrow tumour spectrum is illustrated by BAP1, a 
recently described CPG. Its identification also illustrates the potential utility of 
somatic mutation databases to provide gene candidature. Subsequent association 
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with further tumour types demonstrates the ability of NGS techniques to aid rapid 
definition of a broader phenotype than that described by the original association.    
 
Acting on observational data that suggested hereditary predisposition to uveal 
melanoma (UM) in a proportion of cases, Abdel Rahman et al sequenced BAP1 in 
a series of UM patients with a clinical indication of hereditary susceptibility. 
Candidature of BAP1 had been suggested by a number of lines of evidence 
including a previous study showing that around half of UM’s had a somatic BAP1 
mutation54. BAP1 is located on chromosome 3 and monosomy of this 
chromosome is frequently observed in these tumours55. 1/53 probands was found 
to have a truncating constitutional BAP1 mutation. Their UM demonstrated loss of 
the wild type allele and reduced protein product on immunohistochemistry staining, 
as did a lung adenocarcinoma diagnosed in the proband and a meningioma from a 
mutation carrying relative56. 
 
Since this discovery, mutations in this gene have been associated with a variety of 
other cancers, notably renal cell carcinoma (RCC). Popova et al identified a splice 
site mutation in a family with four individuals affected with RCC. They 
subsequently validated this finding by showing mutations in 11/60 families with 
aggregations of RCC in addition to tumours previously associated with BAP157. 
The mutation identification was obtained through whole-exome sequencing where 
BAP1 was not proposed as an initial candidate, indicating that the non-hypothesis 
based analysis of multiple genes can lead to a greater number of gene-tumour 
associations on a shorter timescale than candidate gene analysis alone.  
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Genotype-phenotype correlation 
When a variant in a CPG is detected by clinical testing, laboratory and clinical 
teams seek to assess that variant's pathogenicity by assessing aspects such as 
the likely effect on the gene product and consistency with the observed 
histopathological characteristics of tumours in the family. If deemed deleterious, 
the patient is frequently managed according to the tumour risks assigned to all 
deleterious variants in that gene. It is well recognised, however, that individual 
variants in the same gene can have contrasting clinical effects. In multiple 
endocrine neoplasia type 2 (MEN2), caused by activating missense mutations in 
the RET proto-oncogene, a variety of tumours are observed including medullary 
thyroid cancer, phaeochromocytoma and parathyroid hyperplasia/adenoma58. The 
level of risk for each of these tumours is influenced by the RET codon affected to 
the extent that mutation status is an integral part of clinical management 
guidelines. For example, mutations in codon 634 are associated with an increased 
risk of phaeochromocytoma and it is recommended to start biochemical screening 
for this at age eight rather than age 20 like for many other mutations59. They are 
also associated with cutaneous lichen amyloidosis, which is not reported for other 
variants60. The p.Met918Thr variant is only associated with the MEN2B clinical 
subtype, which includes some additional features such as gastrointestinal 
ganglioneuromatosis61. Even the finding of a non-sense or frameshift mutation 
may not imply that the function of the gene product is lost and will produce a risk 
profile similar to other patients with only one functional allele of a given gene. The 
BRCA2 c.9976A>T variant introduces a premature stop codon but this is towards 
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the 3' end of the gene and is not considered to significantly increase breast and 
ovarian cancer risk62.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
Section 4 – Multiple Primary Malignant Tumours 
 
Multiple primary malignant tumours in the general population 
Multiple primary malignant tumours (MPMT) describes a clinical scenario whereby 
two or more histologically distinct malignant tumours not due to metastasis, 
recurrence or local spread are diagnosed in the same individual. These may be 
diagnosed at the same time (synchronous) or separated by months to years 
(metachronous). The first description of MPMT is attributed to Billroth in 188963 
and it initially appeared to be a rare phenomenon. However, with improved 
survival from many forms of cancer64, MPMT is increasingly recognised as an 
important clinical problem65. A review of 69 European cancer registries revealed 
that 6.3% of registered tumours were part of an MPMT clinical picture66 and 16% 
of incident cancers reported to National Cancer Institute (USA) in 2003 were in 
individuals with a previous diagnosis of a malignant tumour67.  
 
Furthermore, registry-based evidence suggests that incidence of cancer in 
individuals previously diagnosed with a malignant tumour is greater than the 
expected population incidence, with an increased risk of a wide variety of 
concordant (same site and morphology) and discordant (different site and 
morphology) tumours after an initial primary malignancy. Standardised incidence 
ratio (SIR) is used to measure this and expresses the ratio of observed incident 
cancer cases within a patient series (in this case those who had previously been 
diagnosed with a cancer) compared to incidence expected in a corresponding 
population adjusted for risk factors such as age, sex and socioeconomic status. In 
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a registry containing 633,964 cancer incidences, 8.5% were at least second 
cancers. The overall SIR of cancer in previous cancer patients was 1.3 in men and 
1.6 in women, with 2.4 the highest figure for a discordant tumour in aerodigestive 
tract cancer patients less than one year post diagnosis. Higher SIRs may result 
from a number of factors discussed below. Some SIRs were lower if a cancer 
diagnosis had previously been made (e.g. 0.8 for prostate cancer patients). This 
may be due to treatment for the first tumour that reduces chances of a second 
occurring, especially true of further concordant cancers but also potentially 
applicable to discordant neoplasms (e.g. chemotherapy may also treat occult 
malignancies elsewhere). In addition, poor prognosis for particular cancers may 
lead to less active surveillance and under diagnosis of subsequent cancers 
compared to the general population. For example the SIR for gastric cancer in 
men is 0.6 after 10-38 years68.  
 
Aetiology of multiple primary malignant tumours 
Multiple factors may contribute to the occurrence of MPMT, which may be 
challenging to delineate from one another.  
 
It may occur by chance alone. A rough estimate of how frequent this is arrived at 
by considering the lifetime risk of developing cancer under the age of 60 years69,70 
(this study has used this age cutoff), multiplying that probability and considering it 
in the context of the observed age distribution in a population MPMT cohort65. For 
each age group, an expected number of cases in a given time period could be 
generated. Applied to the West Midlands population, the sum of these figures 
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suggests 16.8 cases per year, but the lifetime risk figure notably does not include 
non-melanoma skin cancer (NMSC). Registry based evidence from the same 
population (1995-1999) showed 1425 new MPMT cases per year including 
NMSC64, which would be estimated to be around 200 per year without NMSC if it 
is considered that these cancers makes up around a 23.6% of diagnoses in the 
UK71 and assumed that these had a typical age distribution and occurred evenly 
among first and second cancers. On this basis, observed MPMT cases appear to 
be more frequent than that expected by chance alone. 
 
Increased clinical surveillance following an initial diagnosis may lead to increased 
detection of second malignancies through lead time bias or may identify cancers 
that would not present otherwise in the individual’s lifetime. Identification of a 
tumour due to these factors may be suggested by a short intervening period 
between diagnoses or even a synchronous presentation. Increased diagnostic 
rates may be seen due to systematic imaging or examination of an organ at risk of 
recurrence, for example regular skin examinations following the diagnosis of 
cutaneous malignant melanoma72. They may also be seen due to surveillance 
imaging modalities that include other organs, as has been reported during positron 
emission tomography/computed tomography follow up for prostate cancer73,74. 
Similarly, surgery for one primary may expose a synchronous tumour. This can 
occur with the diagnosis of endometrial cancer after total abdominal hysterectomy 
and bilateral salpingo-oophrectomy for ovarian cancer75, though it has been 
debated whether this pairing represents true independent primaries.  
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Radiotherapy or chemotherapy administered to treat a first cancer may predispose 
to second primary tumours and even non cytotoxic drug treatment may increase 
cancer risk as is seen for endometrial cancer after tamoxifen treatment for breast 
cancer76.  Treatment related second cancers are often characterized by delayed 
onset and may be observed many years after the exposure to treatment occurred. 
Firm associations between cancer therapy and subsequent primary malignancies 
caused by them are challenging to arrive at for a number of reasons. Many 
cancers carry a poor prognosis and any carcinogenic effect of treatment is unlikely 
to be noted before death occurs. Additionally, treatment regimens are unlikely to 
be constant over time and between centres of care, preventing collation of 
similarly treated cases to follow up in observational studies. This difficulty is 
compounded in the case of tumours that occur infrequently in the population. 
Finally, treatment modalities for particular cancer types may become more 
frequently used in clinical practice with time and tumourigenic effects may be yet 
to manifest themselves. There is recent evidence, for example, that radiotherapy 
in renal cell carcinoma (a tumour that has previously been considered resistant to 
such treatment) may have greater utility than is widely thought77.  
 
Despite these challenges, a number of associations are known that demonstrate 
differences depending on whether chemotherapy or radiotherapy are used. 
Cancers may not be distinguishable from those that are not treatment related but 
delineation of specific features can be rewarding. Leukaemias showing high-grade 
microsatellite instability, for example, are common in therapy related tumours but 
rare where leukaemia is diagnosed without a cancer history78.  
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Radiation induced second cancers generally occur ten or more years after 
exposure79 and many have been documented through observational studies of 
survivors of events such as the Japanese atomic bomb attacks80 and Chernobyl 
nuclear accident81. Solid cancers such as those affecting the thyroid, lung, 
stomach, skin and connective tissue (sarcoma) are more frequent82 with sites 
reflecting tissue sensitivity and region of exposure, though haematological tumours 
such as leukaemias can also occur at increased rates and may occur after shorter 
periods of time83. The link between radiotherapy for Hodgkin’s lymphoma and 
breast cancer is particularly well established and has led to revision in 
management strategies to reduce radiation dosage to breast tissue84–86.  
 
Second cancers caused by chemotherapeutic agents are more often 
haematological in nature and may occur after a relatively short time post 
treatment. Alkylating agents such as etoposide can cause acute myeloid 
leukaemia, usually after five to seven years and leukaemias due to 
epipodophyllotoxins often have a three year latency period87. There are also risks 
of solid tumours associated with chemotherapy, one example being dose 
responsive increased incidence of bladder cancer following cyclophosphamide 
treatment88.  
 
Carcinogenic effects of chemotherapy and radiotherapy are modified by a wide 
range of variables that may interact with one another to modify the risk of further 
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primary cancers. Higher radiation or cytotoxic agent dosage can increase risk to 
tissues through greater potential for mutational events but might also lead to lower 
risk due to induction of cell death in potentially malignant clones78. Tumourigenic 
treatment effects can also be modified by the age at which therapy is 
administered. A younger age at treatment results in a greater duration of time 
where further tumours might occur and many of the known treatment-cancer 
associations have been identified through follow up of children with diagnoses 
such as neuroblastoma89. Biological reasons may, in addition, account for greater 
risks following treatment in childhood and there is evidence that second 
malignancy incidence at a given follow up time point is lower in individuals where 
exposure occurred at a later age79. Theoretical reasons for this might include an 
increased cellular proliferation rate at an earlier age, enhancing clonal expansion 
of cells that have undergone tumourigenic genetic changes and increasing the 
probability of further cancer defining alterations occurring in their daughter cells. 
While chemotherapy exposes a wide range of tissues to its effects, the area 
covered by radiotherapy fields influences which organs are at risk (notwithstanding 
scattered radiation). This is seen following radiotherapy for breast cancer where 
an increased incidence of lung and oesophageal cancers occurs compared to 
patients treated without radiation90. Combination of modalities may complicate the 
picture and can itself be a risk modifying factor. For example, the administration of 
doxorubicin for Wilms tumour increases the risk of breast cancer following 
radiotherapy to treat this malignancy91 and combined chemotherapy and 
radiotherapy for Hodgkin’s lymphoma has been noted to confer higher incidence of 
gastrointestinal malignancies than would be expected if the risks from each 
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modality were added to one another92. Genetic factors may also influence 
likelihood of developing a second tumour due to treatment. Conditions that cause 
cancer susceptibility independently of treatment can enhance risks of radiotherapy 
or chemotherapy and manifestations of this effect include basal cell carcinomas 
following radiotherapy for medulloblastoma occurring in Gorlin syndrome 
patients93 and radiation induced cancers in Li-Fraumeni syndrome94.  More subtle 
modifying effects of genetic factors are exemplified by variation in genes encoding 
cytochrome p450 enzymes, effectively increasing or decreasing the administered 
dose of some chemotherapy agents due to altered metabolism95.  
 
Environmental exposures relevant to the development of two or more cancer types 
account for a proportion of MPMT cases and are important to consider in the 
assessment of such patients. These may be easily identifiable clinically such as a 
smoking history where, for example, an increased risk of oral and pharyngeal 
cancers are observed after an initial lung adenocarcinoma96. However, different 
environmental exposures in the same individual may also contribute to MPMT, 
particularly if those exposures are prevalent in the population. Smoking prevalence 
is estimated at 20% in adults in England97 while obesity is present in ~25%98. A 
simple multiplication of probabilities would indicate that ~5% of adults have both 
exposures but this assumes random distribution of them in the population, which is 
not always the case (two carcinogenic factors that are reported to occur in  
association are smoking and alcohol consumption99). 
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It is widely recognised that genetic susceptibility can be a major cause of MPMT. A 
significant role for genetic factors in MPMT might be suggested by increased 
incidence of second cancers in those with a family history of the same primary 
tumour type (as a surrogate measure of a likely inherited genetic component). 
Studies based on the Swedish Family Cancer Database have shown an increased 
incidence of concordant and discordant second tumours in individuals previously 
diagnosed with breast cancer and with an affected parent. For example, the SIR 
(based on expected population incidence) for ovarian cancer following breast 
cancer was 2.0 in those with a family history of breast cancer and 1.7 in those 
without. The corresponding SIR’s for acute lymphoid leukaemia were 12.7/1.9 and 
4.6/3.0 for breast cancer100. Similarly, greater incidence of a second colorectal 
cancer has also been observed among patients who have a first degree relative 
with the same diagnosis, where a two-fold risk was observed compared to non-
familial cases101. Such observations suggests an observable contribution to the 
burden of second cancers in the general population due to inherited genetic 
factors. 
 
A proportion of multiple cancers is accounted for by cancer predisposition 
syndromes, which may be suggested clinically by factors such as a young age at 
tumour diagnosis or a family history of tumours (though not in de novo cases), 
especially if they are concordant histologically or in keeping with the phenotype 
associated with a particular syndrome (e.g. breast and ovarian cancer in 
BRCA1/BRCA2 mutations and haemangioblastomas and renal cancers in VHL 
disease). Multiple tumours per se are also frequently taken as a clinical indicator. 
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Indeed, many predisposition syndromes are associated with a high frequency of 
the phenomenon102–106. Accordingly many patients with MPMT will be referred for 
evaluation by clinical cancer genetics services with a view to confirming the 
diagnosis of a suspected specific condition and eliciting the causative CPG 
mutation using genetic testing. The outcome of such evaluation has not previously 
been well described.  
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Section 5 - Study Aims 
 
Clinical Genetics referral based series review 
Although there are often large published series of individuals with a specific cancer 
predisposition syndrome, there are no large studies of individuals with MPMT 
referred for clinical genetics assessment. This information may have useful 
implications for clinical and laboratory practice. In particular, it is relevant to know 
whether individuals with MPMT who test negative for a suspected mutation/s 
conferring cancer predisposition are likely to represent phenocopies or whether 
there is evidence to indicate a need for more extensive genetic testing. To address 
these questions a retrospective review of referrals for MPMT to two regional 
genetics centres over a period of 20 years was undertaken, aiming to observe and 
assess: 
1. Tumour types. 
2. Rate of identification of pathogenic variants in CPGs. 
3. Which CPGs contained pathogenic variants identified in the series. 
4. The clinical evidence for undiagnosed pathogenic variants, utilising 
recognised clinical indicators and a newly devised scoring system. 
5. Correlation between the newly devised scoring system and established 
scoring systems to assess likelihood of the presence of a pathogenic 
variant. 
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Candidate gene analysis 
It was hypothesized that a group of patients with MPMT might harbor constitutional 
pathogenic variants in the CPGs TP53, PTEN or CDKN2B and analysis of these 
genes in a subset of individuals was consequently initiated by conventional 
“Sanger” sequencing.  
 
Constitutional mutations in TP53 cause Li Fraumeni syndrome, associated with 
the development of a wide variety of cancers but particularly those of the soft 
tissue, breast, brain and adrenal cortex49. Its protein product, p53 is a critical 
protein in a wide variety of cellular pathways and tumour suppressor functions 
107,108. Mutations in PTEN lead to a spectrum of disorders referred to as PTEN 
Hamartomatous Tumour Syndrome, the most frequent subtype of which is 
Cowden syndrome (CS). CS characteristically causes breast, endometrial and 
thyroid cancers as well as non-malignant features such as macrocephaly and 
developmental delay109. PTEN normally acts to inhibit the PI3K/Akt cellular 
signaling pathway and aberrant function due to PTEN mutation can result in loss 
of this inhibition and reduced apoptosis and cell cycle arrest109. Mutations in either 
gene leads to a phenotype including breast and bowel cancers, which are the 
most common malignancies prompting referral to clinical genetics110. They can 
also both be associated with the development of MPMT and an estimated 15% of 
individuals from Li-Fraumeni kindreds who are diagnosed with cancer go on to 
develop a second malignancy111. Assessments of cancer risks from the largest 
series of PTEN mutation carriers do not include an estimate of multiple primary 
risk per se although many of the cancers that such individuals are predisposed to 
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have individually high risks such as breast (lifetime risk 85%), colorectal (lifetime 
risk 34%) and endometrial (risk by age 60, 30%), suggesting an appreciable rate 
of second cancers112. Clinical testing guidelines for CPGs have been developed to 
target genetic analysis to those more likely to harbour a mutation based on how 
closely their phenotype matches that seen in the putative syndrome as previously 
described. The tumours associated with mutations in a particular gene however, 
may develop over time and as genetic testing becomes more widely 
available/performed. Indeed, the risk of rectal and kidney cancers and melanoma 
in PTEN mutation carriers has only recently been characterised112. Testing MPMT 
cases in this series would assess the relevance of TP53 and PTEN in a less 
phenotypically selected group and positive results would contribute to a better 
definition of the associated tumour phenotype. 
 
A non-sense mutation in CDKN2B has recently been identified as predisposing to 
cancer in a kindred where multiple members were diagnosed with renal cell 
carcinoma (RCC). The family also includes individuals with ovarian, colorectal and 
haematological malignancies. Further study of individuals with evidence of familial 
RCC demonstrated three cases with missense variants in this gene113. There are 
few other reports concerning the tumour spectrum that may be associated with 
constitutional mutations in this gene, though they have been shown to be not 
associated with familial melanoma114,115. CDKN2B is frequently disrupted by 
promoter methylation in a variety of haematological malignancies and encodes 
p15, a protein involved in cell cycle regulation116. Analysis was undertaken to 
assess whether CDKN2B mutations may be (given their recent discovery in cancer 
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predisposition) associated with tumours other than RCC or be present in those 
MPMT patients in this series who have previously been diagnosed with this 
tumour.  
 
Registry series review 
Patient series identified from Clinical Genetics referrals are subject to 
ascertainment biases that can influence their composition. MPMT patients are 
more likely to be referred for assessment if their phenotype is consistent with a 
recognised cancer predisposition syndrome where a genetic test can be offered 
but this may leave many cases un-assessed. Other possible reasons for non-
referral include a poor prognosis after diagnosis preventing further consultations or 
non-genetics clinicians being unaware of the testing available. To assess the 
potential burden of constitutional genetic cancer predisposition in the general 
MPMT population, cases were ascertained from a regional registry and a clinical 
indicator based assessment was applied to predict how many cases might be due 
to a pathogenic variant in a CPG. Comparison with the Clinical Genetics based 
series was made to assess the extent and nature of tumour combinations that 
might not prompt referral but which appear amenable to more extensive genetic 
testing.  
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Chapter 2 - Materials and Methods 
 
Section 1 - Clinical series review 
 
Ascertainment of cases  
In order to identify multiple primary malignant tumour (MPMT) cases referred for 
genetic assessment, a two stage evaluation of patients referred to two UK regional 
genetics services covering a combined population of >10 million117,118 was 
undertaken. Firstly, the database of the West Midlands Regional Genetics Service 
was interrogated to identify individuals with two or more malignant tumours (of 
different types) diagnosed before the age of 60 years. Referrals and genetic 
analysis had taken place between February 1993 and February 2013. Medical and 
pathology records were then inspected to confirm the inclusion criteria. Those 
individuals with metastases, recurrence of the primary tumour or tumours of the 
same site and histological type were excluded from further analysis if those tumour 
characteristics led to non-fulfillment of the criteria. Multifocal cancers were counted 
as a single malignancy. The definition of MPMT was therefore made according to 
international guidelines119. Tumours known to be benign were excluded from 
analysis. In a further stage of ascertainment, two databases for individuals referred 
to the North West Regional Genetics service (in Manchester, UK) with a suspected 
diagnosis of hereditary breast or colorectal cancer were interrogated to identify 
additional cases of MPMT satisfying the same criteria specified above. 
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Case record review 
To provide an indicator, in a wide range of clinical scenarios, of the strength of 
clinical evidence for an inherited cancer syndrome a “multiple tumour score” 
system was developed. To record this score for individuals within the series, 
Clinical Genetics case records were inspected to extract details of family history, 
age at diagnosis and site/histopathological type of cancer. The multiple tumour 
score (MTS) (Table 1) was designed to be analogous to the “Manchester score” 
for prioritising BRCA1/BRCA2 testing in familial breast cancer kindreds120. Within a 
single family lineage, each cancer was assigned a score (Table 1) and the MTS 
calculated as the sum of these scores within a lineage, with one unaffected 
intervening relative permitted between individuals with a cancer diagnosis. A 
higher score was proposed to indicate a higher likelihood of an inherited cancer 
syndrome. Within the scoring system, rare or young onset cancers were weighted 
more heavily than common or later onset cancers (as phenocopies should be less 
likely in the former). Cervical cancer has been estimated to be almost entirely 
attributable to human papilloma virus (HPV) infection22 but has an incidence peak 
at an earlier age than most other cancers in the series121. This may lead to 
overestimation of the likelihood of a predisposing mutation via an elevated MTS in 
families where these cancers appear. Nevertheless, these tumours were included 
in assessment given the incidence rate of cervical cancer when considered in the 
context of high HPV infection prevalence122. As with many cancers, the 
development of this malignancy may involve a degree of genetic predisposition 
acting as a co-factor among individuals with an existing environmental exposure, 
in this case HPV infection. Additional analyses, however, were also performed 
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excluding cases with cervical cancer as part of their MPMT clinical presentation. 
For individuals with a diagnosis of breast or ovarian cancer, the Manchester 
score123 was also calculated and status for the revised Bethesda criteria for MSI 
analysis51 was noted if colorectal or endometrial cancer had been diagnosed. 
Records of genetic testing were interrogated to obtain details of genes tested and 
mutations identified (including whether deemed causative by laboratory/clinical 
team). Statistical significance testing was performed using two tailed z-tests. 
 
Table 1. Multiple tumour score 
Malignant tumour 
Age at 
diagnosis 
Score 
Breast, lung, colorectal, prostate, non-melanoma 
skin, cervical. 
<30 5 
 30-39 4 
 40-49 3 
 50-59 2 
 >59 1 
Any other malignant tumour <50 5 
 50-59 3 
 >59 1 
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Section 2 - Candidate gene testing 
 
DNA samples 
Stored DNA samples extracted in the West Midlands Regional Genomics 
Laboratory were obtained from 62 patients identified by the West Midlands case 
note review. None of these individuals had been identified with a pathogenic 
variant in a cancer predisposition gene following assessment by Clinical Genetics 
services. All patients had given consent for genetic testing to be performed to 
identify a genetic cause of their cancer phenotype. Stock samples were stored at -
20ºc. 
 
Whole genome amplification 
To ensure sufficient DNA quantity for analysis while maintaining a stock, samples 
were subject to whole genome amplification using the REPLI-g Mini Kit (Qiagen, 
Hilden, Germany). The expected yield of DNA from this kit is 10µg, which can be 
generated from DNA quantities as low as 0.1ng. According the manufacturers 
protocol, 5µl of each stock sample solution was initially denatured with 
denaturation buffer, a process which was terminated by addition of neutralization 
buffer. DNA (Phi 29) polymerase was then added to each reaction and incubated 
for 16 hours at 30ºc for amplification to proceed by multiple displacement 
amplification (MDA). MDA utilizes random hexamer primers to bind to sites across 
the genome. Phi 29 polymerase begins amplification at these sites and is able to 
generate large fragments (2 kilobases–100 kilobases) with high fidelity due to its 
3’-5’ proofreading activity124. Each reaction generated 50µl of amplified DNA 
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solution, which was diluted to 1:20 for use in polymerase chain reactions. 
 
Polymerase chain reaction primer design 
To design suitable primers to amplify coding regions of PTEN, TP53 and CDKN2B 
by polymerase chain reaction (PCR), sequences were downloaded from the 
Ensembl genome browser125. Sequences corresponding to regions of interest 
were entered into Primer 3 software126 to generate candidate primer sequences 
producing amplicons representing coding exons. Primer sequences were selected 
on the basis of a number of parameters. The melting temperature (Tm) of a primer 
describes the temperature at which half the primer duplex molecules will become 
single stranded due to denaturation. Sufficient single stranded molecules must be 
available for the annealing phase of the reaction and primer pairs were selected 
where there was a difference of 5ºc or less between the forward and reverse 
primers to ensure a similar ratio of the two species at that phase. Additionally, 
similar Tm’s across different primer pairs were aimed for to ensure that different 
amplicons could be generated with a small number of reaction programmes (i.e. 
on the same 96 well plate). Quality of sequencing readout can be compromised by 
amplicon sizes of more than 500 base pairs and primer pairs were selected to 
ensure that generated fragments were under this size. An adequate number of 
bases 5’ to the start of the region of interest (generally 50) were incorporated into 
amplicons as the first 5’ bases of a sequencing readout are often of lower quality. 
Specificity of primer pairs was checked by inputting the oligonucleotide sequences 
into the Primer BLAST website hosted by the National Centre for Biotechnology 
Information127 to avoid amplification of non-targeted genomic regions. 
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Assessments of potential for secondary primer structure formation provided by 
Primer 3 were also considered as a higher potential indicates lower availability of 
annealing primer oligonucleotides during the reaction process. Primer pairs, once 
selected, were ordered with desalted purification and synthesis scale of 25nmol 
(Sigma Aldrich, St Louis, MO, USA). Sequences are shown in Table 2. On receipt, 
primers were diluted to a 100µM solution with purified water. From these stock 
solutions, 1:10 dilutions were produced for use in PCR reactions. Both stock and 
working solutions were stored at -20ºc. 
 
Table 2 – Primers used: PTEN, TP53 and CDKN2B coding regions 
Amplicon Forward Primer Reverse Primer 
PTEN exon 1 AGAGCCATTTCCATCCTGCAGA 
ACGTTCTAAGAGAGTGACAGAA 
AGGT 
PTEN exon 2 TCTTTCTTTTCATAACTA 
ATCTTTTTCTGTGGCTTAGAAA 
TCTTTTC 
PTEN exon 3 CCATAGAAGGGGTATTTGTTGG ACTCTACCTCACTCTAACAAGCA 
PTEN exon 4 ATTCAGGCAATGTTTGTTAGTAT 
TACAGTCTATCGGGTTTAAGTT 
ATACAA 
PTEN exon 5 GGGGAAAATAATACCTGGCTTCC AAATTCTCAGATCCAGGAAGAGG 
PTEN exon 6 ACCCAGTTACCATAGCAATTTA 
AGAAAACTGTTCCAATACATG 
GAAGGAT 
PTEN exon 7 TGACAGTTAAAGGCATTTCCTG 
TAGCTTTTAATCTGTCCTTAT 
TTTGGATATTT 
PTEN exon 8 GCAACAGATAACTCAGATTGCC CATACATACAAGTCAACAACCCC 
PTEN exon 9 GAGGGTCATTTAAAAGGCCTCT TCATGGTGTTTTATCCCTCTTGA 
   
TP53 exon 2 CACTGGCATGGTGTTGGG TTTTCGCTTCCCACAGGTCT 
TP53 exon 3 TCTCATGCTGGATCCCCACT AGTCAGAGGACCAGGTCCTC 
TP53 exon 4 CCATGGGACTGACTTTCTGC GATACGGCCAGGCATTGAAG 
TP53 exon 5 ACGCCAACTCTCTCTAGCTC TCAGTGAGGAATCAGAGGCC 
TP53 exon 6 TGTTCACTTGTGCCCTGACT TTAACCCCTCCTCCCAGAGA 
TP53 exon 7 CGACAGAGCGAGATTCCATC GGGTCAGAGGCAAGCAGA 
TP53 exon 8/9 TTGGGAGTAGATGGAGCCT AGTGTTAGACTGGAAACTTT 
TP53 exon 10 CAATTGTAACTTGAACCATC GGATGAGAATGGAATCCTAT 
TP53 exon 11 AGACCCTCTCACTCATGTGA TGACGCACACCTATTGCAAG 
   
CDKN2B exon 1 AAGAGTGTCGTTAAGTTTACG ACATCGGCGATCTAGGTTCCA 
CDKN2B exon 2 TGAGTATAACCTGAAGGTGG GGGTGGGAAATTGGGTAAG 
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Polymerase chain reaction 
Whole genome amplified DNA samples were incorporated into PCR reactions on a 
96 well plate according to the reaction constitution outlined in Table 3. The Biomix 
red solution (Bioline, London, UK) contains Taq DNA polymerase, 
deoxyribonucleotide triphosphate molecules (dNTPs), reaction buffers and a dye 
to assist with transfer of reaction products. GC rich solution was incorporated if GC 
content of the amplicon was high and the initial reaction had failed. Control 
reactions without template DNA were included in all sets of reactions where a 
particular primer pair was used.  
 
Table 3- Polymerase chain reaction constituents 
Reaction component Quantity per reaction 
DNA solution (whole genome amplified)   4-5 µl                                                
Water   6.5 µl       
Forward primer 0.5 µl       
Reverse primer 0.5 µl      
Biomix red solution 12.5 µl             
 
 Reactions were run on a Bio-Rad Tetrad Thermal Cycler (Bio-Rad, Hercules, CA, 
USA) according to the programmes described in Tables 4 and 5. For PTEN and 
TP53 amplicons, annealing temperature was variable according to primer pair. 
This was based on the Tm from each primer (2-5c below the lowest in each 
primer pair) but also through optimisation of individual amplicon reactions. A high 
annealing temperature was aimed for as non-specific annealing of primers is less 
likely at higher temperatures. This is offset against a generally higher yield of PCR 
product at lower temperatures due to greater annealing of primers. Tm for 
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CDKN2B reactions was constant as there were only two amplicons. For these 
amplicons, annealing temperature was increased over five denaturation-
annealing-polymerisation cycles in the early part of the reaction. This was intended 
to optimise specificity of PCR products (at the expense of yield) in the earliest 
phase of the reaction. A population of specific products allows a lower annealing 
temperature to be used in later cycles, optimising yield while minimising 
amplification of the now less abundant non-targeted genomic areas. 
 
Table 4 – Thermal cycling programmes used for polymerase chain reactions: 
PTEN and TP53 
Reaction step Temperature Duration Cycles 
1 95c 10 mins  
2 95c 60 secs  
3 
Variable dependent on 
primer pair (55-64c) 
60 secs  
4 72c 90 secs 
Return to 
step 2 x39 
5 72c 10 mins  
 
Table 5 – Thermal cycling programmes used for polymerase chain reactions: 
CDKN2B 
Reaction step Temperature Duration Cycles 
1 95c 5 mins  
2 95c 45 secs  
3 58-62c 45 secs  
4 75c 45 secs 
Return to step 2 x4. Increase 
step 3 temp by 1c each 
cycle 
5 95c 45 secs  
6 54c 45 secs  
7 72c 45 secs Return to step 5 x36 
8 72c 5 mins  
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To observe the PCR reaction’s specificity and yield, agarose gels were produced 
by adding ethidium bromide (1µl per 100ml) to 1% agarose solution (agarose 
powder in Tris Acetate Ethylenediaminetetraacetic acid (EDTA) buffer). A sample 
of each PCR reaction was added to wells incorporated in the gel, which was 
bathed in Tris Acetate EDTA buffer. Following a 20 minute period run at 180v, the 
gel was removed and photographed under ultraviolet light to visualise DNA. A 
single clear band on the gel denoted a specific product with good yield suitable for 
sequencing. PCR products were not used for sequencing if there was evidence of 
non-specificity of the reaction, seen as blurred bands on the gel indicating 
amplicons of various sizes (i.e. not at the same genomic location) being produced. 
If reaction products were observed from control wells then reactions corresponding 
to that amplicon pair were rejected as this indicated contamination.  
 
Sequencing reaction 
2.4µl PCR reaction products were cleaned by adding an equal volume of 
microCLEAN (Microzone, Haywards Heath, UK) and centrifuging at 4000RPM for 
40 minutes. The supernatant was then discarded by inverting the 96 well plate 
containing the products onto a paper towel and centrifuging at 500RPM for 30 
seconds. The remaining DNA pellet was subsequently incorporated into a 
sequencing reaction comprising of (per reaction) 0.5µl BigDye® Terminator v3.1 
Ready Reaction Mix (containing labelled chain terminating dideoxyribonucleotide 
triphosphate molecules (ddNTPs), deoxyribonucleotide triphosphate molecules 
(dNTPs) and DNA polymerase) and 2µl 5X sequencing buffer from the BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Austin TX, USA). Also 
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added were 2ml of 2mM primer solution (either forward or reverse primer) and 
5.5µl water. The reactions were run on a Bio-Rad Tetrad Thermal Cycler (Bio-Rad, 
Hercules, CA, USA) with a programme described in table 6. 
 
Table 6 – Sequencing reaction thermal cycling programme 
Reaction step Temperature Duration Cycles 
1 95c 1 min  
2 95c 30 secs  
3 60c 30 secs  
4 60c 4 min Return to step 1 x 34 
5 12c 10 min  
 
Sequencing reaction products were precipitated using a two stage ethanol based 
protocol. In the first stage, 2 µl 0.125M EDTA and 30 µl 100% ethanol was added 
to each well. The plate was centrifuged at 2000RPM for 20 mins and the 
supernatant removed by inverted centrifuging (on a paper towel) at 450RPM for 30 
seconds. In the second stage, 90 µl 70% ethanol was added to each well and the 
plate centrifuged at 2000RPM for 10 mins. Supernatant was removed in the same 
fashion as in the first stage. 10 µl HiDi Formamide (Life Technologies, Carlsbad, 
CA, USA) was added to the remaining pellet in each well, which was subjected to 
a denaturation step by exposure to 95c for two minutes then snap chilled on ice. 
Plates were subsequently loaded onto an ABI 3730 automated sequencer (Applied 
Biosystems, Norwalk, CT, USA).  
 
Sequencing data analysis 
Obtained chromatograms were analysed for variants visually and with the 
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assistance of the Mutation Surveyor software package (Softgenetics, State 
College PA, USA) using reference sequences generated from the GRCh37 human 
genome assembly128. 
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Section 3 - Registry review 
 
Ascertainment of cases 
A series of individuals with more than one diagnosis of a malignant tumour was 
ascertained from the National Cancer Registration Service – Eastern Office, which 
covered a five-year period from 2009 to 2014. Only cases who had developed two 
cancers before the age of 60 years or three cancers before the age of 70 years 
were considered. All cancer sites were included but two or more malignancies in 
the same organ pair only counted as one tumour. Cases were reviewed and 
excluded if they did not fulfil the International Agency for Research on Cancer 
criteria for the classification of multiple primary cancers119. These criteria stipulate 
that cancers occurring at the same site may be classified as separate primaries if 
they fall into different histological groupings. For this reason, haematological 
tumours were subdivided into groups according to their cell lineages as described 
in the guidelines. Basal cell and squamous cell carcinomas of the skin counted as 
separate cancers but were also considered together as non-melanoma skin 
cancer (NMSC). 
 
Collation and grouping of tumour combinations 
Each combination of tumours that occurred in an individual patient was recorded 
along with the five year age band at which that combination had occurred (i.e. the 
age at which the later tumour of that particular combination had been recorded). 
Every combination of two tumours was considered. Thus, if an individual had been 
diagnosed with tumour A and B, then this was recorded as combination A-B. If 
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diagnoses had been made of tumours A, B and C, then this was recorded as 3 
different combinations (A-B, A-C and B-C). To assess which combinations of 
cancers were more likely to be due to genetic predisposition, criteria were applied 
to the series based on population incidence and the relative known contribution of 
environmental exposure. To identify common tumours, a list of the five most 
frequent tumours in the UK population was used, namely breast, lung, colorectal 
and prostate cancer and NMSC129. To consider tumours less likely to be due to 
environmental exposure, cancers with a population attributable fraction (PAF) of 
greater the 50% were recorded. PAF is an estimate of the proportion of incident 
cancers due to a recognised environmental exposure and is based on a large 
scale analysis of the relative contribution of 14 such exposures undertaken in a UK 
population22.  
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Chapter 3 - Results 
 
Section 1 – Clinical Genetics series review 
 
Evaluation and analysis of West Midlands MPMT series 
212 individuals (with 441 tumours) referred for genetic evaluation of a multiple 
primary malignant tumour (MPMT) phenotype satisfied the eligibility criteria for 
inclusion in the study. Most individuals (179, 84.4%) were female and breast 
cancer was the most frequent tumour type (Table 7). The most frequent 
combination of tumour types was breast with ovarian followed by breast with non-
melanoma skin cancer, endometrial and colorectal cancers respectively (Table 8). 
 
Table 7 – West Midlands MPMT series subgroups  
5 most 
common 
tumour types 
All tumours  
(n=441) 
Testing sent 
(n=234) 
No testing 
sent (n=208) 
Test+ve  
(n=96) 
Test-ve   
(n=138) 
Breast 128 (29%) 69 (29.5%) 59 (28.3%) 21 (21.9%) 48 (34.8%) 
Ovarian 54 (12.2%) 35 (14.9%) 18 (8.6%) 14 (14.6%) 21 (15.2%) 
Colorectal 71 (16.1%) 34 (14.5%) 37 (17.8%) 21 (21.9%) 13 (9.4%) 
Endometrial 43 (9.7%) 28 (12%) 16 (7.7%) 12 (12.5%) 16 (11.6%) 
NMSC 42 (9.5%) 22 (9.4%) 21 (10.1%) 7 (7.3%) 15 (10.9%) 
Other tumours 
comprising < 
5% total 
103 (23.3%) 46 (19.6%) 57 (27.4%) 21 (21.9%) 25 (18.1%) 
NMSC – Non melanoma skin cancer 
 
111 of 212 probands (52.3%) had been tested for constitutional mutations in at 
least one gene relevant to inherited cancer (BRCA1 (n=70 individuals), BRCA2 
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(n=67), MSH2 (n=31), MLH1 (n=30), MSH6 (n=11), PMS2 (n=2), APC (n=2), 
MUTYH (n=4), PTEN (n=4), TP53 (n=3), RB1 (n=2). Comparison of tumour types 
between the 111 patients tested for mutations in one or more genes and the 101 
individuals who were not tested revealed broadly similar tumour frequencies with 
only thyroid cancer (higher, p=<0.05) and ovarian cancer (lower, p=<0.05) being 
significantly different in the untested group. The proportionally fewer colorectal 
cancers (Table 7) in the tested group is likely due to 25/101 cases who did not 
undergo germline genetic testing following negative microsatellite instability (MSI) 
and/or immunohistochemistry (IHC) testing indicating insufficient evidence of a 
constitutional mismatch repair gene mutation/Lynch syndrome to justify further 
analysis. There were no differences in gender distribution between tested and 
untested groups (94/111 (84.7%) female in tested group and 86/101 (85.1%) 
female in untested group) but the mean age at diagnosis of first (41.5 vs 43.2), 
second/synchronous (48.8 vs 50.7) and all (45.2 vs 47.3) tumours was lower in 
those who had undergone testing. Where a particular tumour occurred and a 
genetic test was performed, a mutation was identified in the patient diagnosed with 
that tumour in between 27.3% (non-melanoma skin) and 61.8% (colorectal) of 
cases (Table 9). The relatively high mutation rates for colorectal and endometrial 
tumours are again likely due to Lynch syndrome investigations instigated prior to 
germline testing. 
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Table 8 – Tumour combinations observed. West Midlands MPMT series 
 
Quantities indicate number of combinations between x axis tumour and y axis tumour observed in series. Tumour site 
abbreviations on x axis correspond to tumour sites on y axis. NMSC – Non melanoma skin cancer, CNS – Central nervous 
system, CRC – Colorectal cancer. 
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Table 9 – West Midlands MPMT testing sent group – Positive mutation 
testing results by tumour type  
Tumour type 
Number of occurrences where 
patient was mutation positive 
Breast 21 (30.4%) 
Ovarian 14 (40%) 
Colorectal 21 (61.8%) 
Endometrial 11 (39.3%) 
Non melanoma skin 6 (27.3%) 
Other tumours individually 
comprising < 5% total 
22 (47.8%) 
 
Overall, 44 of the 111 (39.6%) patients who underwent germline genetic testing in 
one or more genes had a pathogenic variant demonstrated (designated Test+ve 
group) and 67 did not (designated Test-ve group). 25 cases had negative MSI 
and/or IHC analysis for suspected Lynch syndrome and did not proceed to 
germline testing. These cases were not assigned Test-ve status due to the fact 
that the sensitivity of these investigations is quoted as between 55% and 83% 
depending on gene involved and the assay. Similarly, four cases who had positive 
MSI/IHC but didn’t have a germline test (due to death in three cases) were not 
assigned Test+ve status due to high but incomplete specificity130. These 
individuals are nevertheless likely to have a mismatch repair deficit and further 
calculations were performed (see below) where these investigations were taken as 
negative or positive genetic tests respectively.  
 
Pathogenic variants were most frequent in mismatch repair genes (n=21, MSH2 
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(n=9), MLH1 (n=9), MSH6 (n=3)) or BRCA1/BRCA2 (n=16, BRCA1 (n=12) and 
BRCA2 (n=4)). Seven patients harboured pathogenic variants in genes relevant to 
rarer syndromes (PTEN ((n=3), RB1 (n=2), APC (n=1), MUTYH (homozygous) 
(n=1)). Comparison of the Test+ve and Test-ve groups revealed that the mean 
multiple tumour score (MTS) was significantly higher (21 vs 14.1, p= <0.01) and 
the mean age at tumour diagnosis lower, though not statistically significant, (44 vs 
46, p= 0.3271) (Table 10) in the Test+ve group. The proportion of cases with a 
concordant tumour in a first degree relative was also higher in the Test+ve group 
(63.6% vs 56.7% p= 0.4654) though again, this was not statistically significant. 
 
Table 10 – Clinical parameters observed in West Midlands MPMT series 
 
All cases  
(n = 212) 
Mutation 
identified 
(Test+ve) (n 
= 44) 
No mutation 
identified. ≥ 1 
germ-line test 
(Test-ve) (n = 
67) 
No mutation 
identified  
(n = 168) 
Mean age at tumour 
diagnosis 
46.2 SD 10.2 44 SD 10.9 
46 (SD 9.8 
p= 0.3271) 
46.8 (SD 9.9 
1.85 p= 0.064) 
Mean age diagnosis 1st 
tumour 
42.5 SD 11.3 39.4 SD 12.3 
42.9 (SD 10 
p= 0.1141) 
43.1 (SD 10.7 
p= 0.368) 
Mean age diagnosis 2nd or 
synchronous tumour 
49.6 SD 7.4 48.1 SD 6.8 
49.2 (SD 8.4 
p= 0.4473) 
50.1 (SD 7.2 
p= 0.089) 
Mean individual age at 
tumour diagnosis 
46.2 SD 8.4 44.2 SD 8.6 
46 (SD 8.6 
p= 0.2801) 
46.7 (SD 8.3 
p= 0.082) 
% cases with individual 
mean age at tumour 
diagnosis ≤ Test+ve group 
median (= 46.25 ) 
N/A N/A 41.8 (28) 
39.9 (67) 
 
% cases with concordant 
tumour in 1st degree relative 
52.3 (111) 63.6 (28) 
56.7 (38) 
p= 0.4654 
49.4 (83) 
p= 0.093 
Mean multiple tumour score 14.6 SD 8.7 21 SD 14.3 
14.1 (SD 5.4 
p <0.01) 
12.9 (SD 5.6 
p <0.01) 
% cases with multiple 
tumour score ≥ Test+ve 
group median (=17) 
N/A N/A 
28.3 (19) 
 
21.4 (36) 
Mean individual age at diagnosis = Combined age of tumours ÷ number of tumours in individual. P 
values describe two tailed comparison with Test+ve group (H0 = µ1 = µ2). 
 
There was, however, significant overlap between the MTS in the Test+ve and 
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Test-ve groups such that ~ 28% of Test-ve patients had a value equal to or higher 
than the median seen in the Test+ve group (Fig 2) and 88% (59 cases) had a 
score equal to or higher than the lowest value in the Test+ve group. 21.4% of all 
cases without a mutation demonstrated (including those who had no genetic 
testing performed) had a score equal to or higher than the Test+ve group median. 
The individual mean age at tumour diagnosis (combined ages at diagnosis ÷ 
number of primary tumours) was also calculated and 41.8% of Test-ve cases had 
an individual mean diagnosis age at or below the median value observed in the 
Test+ve group (Fig 3).  This figure was 39.9% if mutation status unknown 
individuals that had not undergone mutation analysis were also included in 
analysis. If the results of MSI/IHC analysis were given equal status to that of 
germline genetic testing then similar figures were observed. 28.1% of the revised 
Test-ve group had an MTS at or above the revised Test +ve median and 38.6% 
had an individual mean age of diagnosis equal to or below the revised Test +ve 
median. 55% had a first degree relative with a concordant tumour compared to 
62.5% in the revised Test+ve group. 
 
Figure 2 - Multiple tumour scores in Test-ve group 
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Figure 3 - Individual mean age at tumour diagnosis in Test-ve group 
 
 
As previously mentioned, analysis was also performed without the cervical 
cancers present in the patients within the series. This led to the exclusion of nine 
individuals, five of whom had received genetic testing with a mutation identified in 
four (BRCA1, BRCA2 x2 and APC). One tumour was discounted that was 
diagnosed in a patient with two other primaries. Results are shown in Appendix 1 
and 2 and correspond to the previous Tables 7 and 10. No significant differences 
in results were shown between the two analyses both in terms of tumour profile 
and clinical indicators of a causative mutation. 
 
Comparison of Multiple Tumour Score with existing scoring systems  
To investigate further the outcome of genetic evaluation in MPMT referrals, the 
characteristics of 240 further MPMT cases referred to the North West Regional 
Genetics Service were analysed. 230 (95.8%) cases had at least one diagnosis of 
breast, ovarian, colorectal or endometrial cancer. 166 (69.1%) cases had received 
a diagnosis of breast and/or ovarian cancer and 144 (60%) had previously had 
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colorectal and/or endometrial malignancy. Details of the individual tumour 
combinations are shown in Table 11. Breast with ovarian cancer was again the 
most frequent combination followed by colorectal with endometrial, colorectal with 
breast and endometrial with ovarian malignancy. 
 
The data from these North West cases were combined with that from the West 
Midlands investigation patients who had breast and/or ovarian cancer (combined 
total n=320) or colorectal and/or endometrial cancer (combined total n=244). The 
relationships between MTS and Manchester score (a measure of indication for 
BRCA1/BRCA2 testing) and MTS and fulfillment of revised Bethesda criteria in the 
two cancer phenotype subgroups were then investigated and are shown in Figure 
4 and Figure 5 respectively. Manchester score showed a positive correlation with 
MTS. Among the colorectal/endometrial cases, 58 (23.8%) had an MTS higher 
than 20. Four out of the 59 (6.8%) individuals not fulfilling the Revised Bethesda 
criteria had scores above this level, therefore the proportion of patients with the 
highest MTS were less likely to fall short of criteria fulfillment. 
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Figure 4 – Correlation of multiple tumour scores and Manchester scores in 
Clinical Genetics combined series 
 
 
Figure 5 – Multiple tumour scores and Revised Bethesda criteria in patients 
with colorectal and/or endometrial cancers in Clinical Genetics combined 
series 
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Thyroid     1   2                   
Ureter    1 1   4 1        1      1     
Table 11 – Tumours combinations observed. North West Regional 
Genetics Service series 
 
Quantities indicate number of combinations between x axis tumour and y axis tumour 
observed in series. Tumour site abbreviations on x axis correspond to tumour sites on 
y axis. NMSC – Non melanoma skin cancer, CNS – Central nervous system, CRC – 
Colorectal cancer. 
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Section 2 – Candidate gene testing 
 
The overlap between Test+ve and Test-ve groups in MTS distributions and age at 
diagnosis suggested that some of the Test-ve group might harbour a mutation in a 
cancer predisposition gene (CPG) that had not been analysed as part of clinical 
service provision.  
 
To test this hypothesis, sequencing of the coding regions of PTEN and TP53 was 
performed in 62 patients not previously tested for mutations in these genes. The 
details of the tumour phenotypes of the 62 patients are shown in Table 12. 56 of 
the 62 (90.3%) patients had been diagnosed with a tumour previously associated 
with mutation in PTEN and/or TP5349,109 (breast cancer in 42 patients, endometrial 
carcinoma (n=10) papillary thyroid cancer (n= 2), sarcoma (n=1) and gliomas 
(n=1)). 41 of the 62 (66.1%) had previously undergone testing on their 
BRCA1/BRCA2 and/or mismatch repair genes. No germline test had been 
performed in 21 cases, eight of whom had negative MSI and/or IHC analysis. The 
13 remaining untested patients all had been diagnosed with breast cancer in 
combination with another tumour but there were no colorectal cancers among this 
group.  
 
No pathogenic or candidate mutations were detected in PTEN or TP53. The TP53 
Pro72Arg common variant was observed in the samples although the genotype 
distribution (C;C ~10%, C;G ~30%, G;G ~60%) among the series was similar to 
that expected in a European population131 and no phenotypic differences were 
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observed between the genotype groups separated on the basis of this variant. 
 
Of the 62 cases tested for PTEN and TP53 variants, 53 were also tested for 
CDKN2B, with those not undergoing analysis indicated by an asterisk in Table 12. 
A heterozygous c.20G>A p.Gly7Asp (rs150973276) variant was detected in one 
case. This individual had been diagnosed with breast and cervical cancers at the 
ages of 52 and 53 respectively. Family history included a son who died from 
choricarcinoma at age 46 and two sisters who had breast cancer at 72 and 73. Her 
father had lung cancer at 50 and paternal uncle died from an unknown primary 
cancer aged between 30-35 (unpublished data).  
 
This variant is rare (minor allele frequency of 0.0077% on Exome Variant 
server132), conserved (GERP score 2.92 (range -12.3 to 6.17)133) and predicted to 
be possibly damaging based on the in-silico predicted effect of amino acid 
substitution (Polyphen score 0.933134). However, it has not previously been 
reported clinically and does not appear on the mutation databases ClinVar135, 
Human Gene Mutation Database136 or the Leiden Open Variant Database137.  
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Table 12 (i) - Tumour phenotypes in cases undergoing mutation analysis of 
PTEN/TP53/CDNK2B (*not tested for CDKN2B mutations) 
Case Tumour type – 1st 
tumour 
Age Tumour type – 2nd or 
synchronous tumour 
Age Further tumours  
1 Ovarian carcinoma 22 Breast carcinoma 42   
2 Hodgkin’s lymphoma 23 Bone sarcoma 27 Breast carcinoma 39 
3 Cervical squamous cell 
carcinoma 
28 Breast carcinoma 49  
4* Breast carcinoma 29 Thyroid papillary 
carcinoma 
38  
5 Anal squamous cell 
carcinoma 
29 Breast carcinoma 30  
6 Melanoma 31 Breast carcinoma 40  
7* NMSC (BCC) 31 Endometrial carcinoma 42 Ovarian carcinoma 42 
8 Cervical squamous cell 
carcinoma 
31 Breast carcinoma 51  
9 Colorectal carcinoma 31 Kidney renal cell 
carcinoma 
44  
10 Ovarian carcinoma 33 Endometrial 
adenocarcinoma 
35  
11 Thyroid papillary carcinoma 35 Breast carcinoma 54  
12 Breast carcinoma 36 NMSC (SCC) 47  
13 NMSC (basal cell 
carcinoma) 
36 Breast carcinoma 37  
14 Anal squamous cell 
carcinoma 
37 Breast carcinoma 42  
15 Polycythaemia rubra vera 37 Breast carcinoma 39  
16 Melanoma 38 Breast carcinoma 47  
17 Breast carcinoma 38 NMSC (BCC) 56  
18* Breast carcinoma 39 Bladder TCC 42  
19 NMSC (BCC) 40 Ovarian carcinoma 55  
20 Breast carcinoma 40 Endometrial carcinoma 54  
21 Ovarian carcinoma 40 Colorectal carcinoma 40  
22 Breast carcinoma 41 NMSC (BCC) 55  
23 Melanoma 41 Breast carcinoma 47  
24 Breast carcinoma 42 Ovarian carcinoma 47  
25 Colorectal carcinoma 43 Endometrial carcinoma 51  
26 Breast carcinoma 43 Endometrial 
adenocarcinoma 
47  
27* Breast carcinoma 43 Ovarian carcinoma 54  
28 Bladder transitional cell 
carcinoma 
43 NMSC (BCC) 51  
29 Colorectal carcinoma 44 NMSC (BCC) 24  
30* Melanoma 44 Breast carcinoma 50  
31 Colorectal carcinoma 44 Breast carcinoma 50  
NMSC – Non-melanoma skin cancer. BCC – Basal cell carcinoma. SCC – Squamous cell 
carcinoma. TCC – Transitional cell carcinoma 
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Table 12 (ii) - Tumour phenotypes in cases undergoing mutation analysis of 
PTEN/TP53/CDNK2B (*not tested for CDKN2B mutations) 
Case Tumour type – 1st Age Tumour type – 2nd 
synchronous tumour 
Age Further tumours  
32 Breast carcinoma 46 Endometrial carcinoma 59  
33 Colorectal carcinoma 46 Breast carcinoma 54  
34 Melanoma 46 Breast carcinoma 47  
35 Colorectal carcinoma 46 Endometrial carcinoma 48  
36 Non melanoma skin cancer 
(basal cell carcinoma) 
46 Colorectal carcinoma 55  
37 Breast carcinoma 47 Renal cell carcinoma 51  
38 Colorectal carcinoma 47 Prostate 
adenocarcinoma 
56 Gastric adenocarcinoma 57 
39* Brain, oligodendroglioma 48 Breast carcinoma 51  
40 Cerebellar tonsil 
ganglioglioma 
48 Colorectal carcinoma 52  
41† Breast carcinoma 48 Ovarian carcinoma 53 Endometrial carcinoma 53 
42 Thyroid follicular 
adenocarcinoma 
48 Breast carcinoma 57  
43* Breast carcinoma 48 NMSC (BCC) 50  
44* Breast carcinoma 48 Endometrial carcinoma 52  
45 Bladder TCC 48 Colorectal carcinoma 52  
46 Ovarian carcinoma 49 Breast carcinoma 50  
47 Breast carcinoma 49 Non-Hodgkin lymphoma 59  
48 Breast carcinoma 50 Melanoma 52  
49 Colorectal carcinoma 51 Breast carcinoma 53  
50 Breast carcinoma 52 Thyroid papillary 
carcinoma 
59  
51 NMSC (BCC) 53 Breast carcinoma 54  
52 Ovarian carcinoma 54 Breast carcinoma 59  
53 Pancreatic adenocarcinoma 54 Colorectal carcinoma 59  
54 NMSC (multiple BCC) 54 Breast carcinoma 54  
55 Colorectal carcinoma 54 Endometrial carcinoma 54  
56 Kidney renal cell carcinoma 55 Gastric adenocarcinoma 59  
57* NMSC (BCC) 56 Breast carcinoma 59  
58 Thrombocythaemia 56 Breast carcinoma 56  
59 Lung carcinoma 56 Ovarian carcinoma 57  
60 Lung carcinoma 56 Ovarian carcinoma 57  
61 Ovarian carcinoma 57 Endometrial 
adenocarcinoma 
57  
62 Lung carcinoma 57 Ovarian carcinoma 59 Bladder carcinoma 57 
NMSC – Non-melanoma skin cancer. BCC – Basal cell carcinoma. SCC – Squamous cell 
carcinoma. TCC – Transitional cell carcinoma 
† Also cervical adenocarcinoma aged 53 
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Section 3 – Cancer registry Review 
 
In order to assess the frequency/nature of MPMT occurring in the UK population 
and compare it with a Clinical Genetics based series, information was obtained 
from the National Cancer Registration Service – Eastern Office, which covers a 
population of 5.5. million138. The database was interrogated to identify individuals 
who had been diagnosed with two or more cancers before the age of 60 years, or 
three or more cancers before 70 where the most recent cancer diagnosis had 
been made during a five year period since January 2009.  In total, 530 cases were 
observed representing 1191 tumours. Because a constitutional genetic cancer 
aetiology is suggested by an earlier age of diagnosis, individuals were separated 
into two groups on the basis of whether their second cancer had been diagnosed 
at under 50 years or after this age. The older age group contained 395 individuals. 
901 tumours were observed, which could be categorised into 38 subgroups on the 
basis of site and histology. The younger age group contained 135 individuals. 290 
tumours were observed, which could be categorised into 33 subgroups. 
Subgroups and their frequency are listed in Appendix 3 and the most common are 
listed in Table 13.  
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Table 13 – Most frequent tumours in cancer registry series 
Cancer type Frequency Cancer type Frequency 
NMSC  24.6% (n=222) NMSC 20.7% (n=60) 
Breast 14.4% (n=130) Breast 18.0% (n=52) 
Malignant 
melanoma 
8.1% (n=73) Malignant melanoma 13.1% (n=38) 
Prostate 8.0% (n=72) Haematological B-cell 5.9% (n=17) 
Colorectal 6.3% (n=57) Thyroid 3.4% (n=10) 
NMSC – Non-melanoma skin cancer 
 
Skin cancers were collectively the most common group followed by the common 
cancers of breast, prostate and colorectal. The three most common cancers were 
the same in both age groups but haematological tumours of B cell lineage and 
thyroid cancers were more frequent in the younger patients. 
 
627 cancer combination occurrences (some individuals had more than one 
combination if diagnosed with more than two malignancies) were observed in the 
after age 50 group, which represented 153 combination types. The before 50 
group contained 178 combination occurrences which fell into 85 combination 
types. Comparison of tumour combinations between the groups is illustrated in 
table 14. The most frequent combinations involve similar cancers though prostate 
and colorectal tumours were more frequent in the older age group. 
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Table 14 – National Cancer Registration Service – Eastern Office series 
tumour combinations representing >2% total in under 50 and over 50 cases 
≥2 tumours 
under 50 (135 
cases) 
% of total 
combinations 
(n=178) 
≥2 tumours not until 
after 50 (395 cases) 
% of total 
combinations 
(n=627) 
Melanoma - 
NMSC 
13 Breast - NMSC 9.2 
Breast - NMSC 12.4 Melanoma - NMSC 8.9 
Breast - 
Melanoma 
6.2 NMSC - Prostate 5.7 
Breast - 
Endometrial 
3.4 Haem B cell - NMSC 5 
Haem B cell - 
NMSC 
3.4 Breast - CRC 3.2 
  Breast - Endometrial 3 
  CRC - NMSC 2.7 
  Breast - Melanoma 2.4 
  Haem B cell - Prostate 2.2 
  Aerodigestive - NMSC 2.1 
NMSC – Non-melanoma skin cancer 
 
To assess, from the available information, the evidence for genetic cancer 
predisposition in the registry series, each tumour was assigned a status based on 
UK population frequency and population attributable fraction (PAF). A summary of 
these parameters applied to the series is shown in Table 15. In the younger age 
group, there was a significantly higher frequency of combinations where both 
tumours were not common and where both tumours were not common and had a 
low PAF. 
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Table 15 - Comparison of National Cancer Registration Service – Eastern 
Office series tumour combinations by epidemiological characteristics of 
tumours under 50 vs over 50 
Tumour 
combination 
characteristics 
≥2 tumours under 
50 (178 
combinations) 
≥2 tumours not 
until after 50 (627 
combinations) 
p value 
1 tumour not 
common 
142 (79.8%) 464 (74.0%) 0.11 
Both tumours not 
common 
50 (28.1%) 99 (15.8%) 0.0002 
1 tumour low PAF 147 (82.6%) 499 (71.6%) 0.37 
Both tumours low 
PAF 
63 (35.4%) 223 (35.6%) 0.97 
1 tumour low PAF 
and not common 
 99 (55.6%) 304 (48.5%) 0.93 
Both tumours low 
PAF and not 
common 
32 (18.0%) 59 (9.4%) 0.00142 
PAF – Population attributable fraction 
P values describe two tailed comparison between groups (H0 = µ1 = µ2) 
 
The West Midlands Clinical Genetics MPMT series (WM series) was compared to 
the population based series to observe differences in terms of tumours occurring. 
The WM series consists of individuals diagnosed with two separate cancers before 
the age of 60 so only those from the registry series fitting these criteria were 
considered.  
 
The WM series, corresponding to a twenty year referral period, contained 212 
cases and 441 tumours whereas the revised registry series contained 472 cases 
and 1013 tumours that occurred over a five year period. The most frequent 
cancers are compared in Table 16. 239 tumour combination occurrences and 66 
71 
 
combination types were observed in the WM series. The revised registry series 
contained 614 combination occurrences and 157 combination types. Combinations 
are shown in Table 17 and compared with the WM series in Table 18. 
 
Table 16 – Most frequent tumours in National Cancer Registration Service – 
Eastern Office (≥2 tumours under 60 cases) and West Midlands series  
Registry (n=1013) 
Tumour number 
recorded 
West Midlands 
(n = 441) 
Tumour 
number 
recorded 
NMSC  249 (24.6%) Breast 128 (29%) 
Breast  167 (16.5%) Ovarian 54 (12.2%) 
Melanoma 97 (9.6%) Colorectal 71 (16.1%) 
Haem B cell  72 (7.1%) Endometrial 43 (9.7%) 
Prostate  59 (5.8%) 
Non-melanoma 
Skin 42 (9.5%) 
Colorectal 53 (5.2%)   
NMSC – Non-melanoma skin cancer 
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Adrenal  
Aerodigestive   
Anal    
Biliary     
Bladder      
Breast  5 2 1 1  
Cervix      7  
CNS      2   
CRC  1  1 1 16 1   
Endometrial  2  1  24 3  2  
Eye      1      
Gastric      1       
Haem 
(Lymphoblastic) 
             
Haem (B-cell)  3   1 13   6 2     
Haem ( Mast cell)                
Haem (Myeloid) 1            1 1   
Haem (T cell)  1    1       1 3    
Kidney  1    1   2     4     
Liver              1      
Lung  2    3 2  1 1    2    2   
Mediastinum         1             
Melanoma  3   1 21 1 1 3     4 2     2   
Mesothelioma                        
Neuroendocrine  1   1 2   1   1        1     
NMSC 1 13 1 1 4 75 2 1 15 9 1 2 1 30  1 3 4  2  68    
Odontogenic                           
Oesophagus                         2   
Ovary      11   4 10    2      1  1  1 6    
Pancreas                        1      
Parathyroid                  1             
Penis                    1      1      
Prostate  4   10    2     10  1  2  1  5  2 26        
Salivary gland         1     1  1  1  1     2         
Sarcoma 2 1    2  1  1    1      1  1  1 5   1    1 1  
Skin other      3                              
Small bowel                         1            
Testis  1  1     3     1  1    1  4   4       3      
Thymus                         2              
Thyroid 1 2 1   1 1 1 1 1   1 4      1  2   9       2 1 2      
Ureter          1    1                           
Uterus                                       1   
Vulva      2                   2                  
Table 17 - Tumours observed in National Cancer Registration Service – 
Eastern office series 
Quantities indicate number of combinations between x axis and y axis tumour observed in series 
CNS – Central nervous system. CRC – Colorectal. NMSC – Non melanoma skin. 
Yellow – Combination represents ≥2% total 
Red – Population attributable fraction >50%. Blue – Among most frequent 5 UK tumours. Green – PAF ≤50% 
and among most frequent 5 UK tumours. 
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Table 18 - Tumour combinations representing >2% total in revised National 
Cancer Registration Service – Eastern Office (≥2 under 60 cases) and West 
Midlands series (≥2 tumours under 60 cases) 
Registry 
% of total 
combinations 
(n=614) 
West Midlands 
% of total 
combinations 
(n=239) 
Breast-NMSC 12.2 
Breast-Ovary
  
11.7 
Melanoma-NMSC
  
11.1 Breast-NMSC 8.4 
Haem B cell-NMSC 4.9 Breast-Endometrial 8 
NMSC-Prostate 4.2 Breast-CRC 6.7 
Breast-Endometrial 3.9 Breast melanoma 5.4 
Breast-Melanoma 3.4 CRC-NMSC 5.4 
Breast-CRC 2.6 Endometrial-Ovary 5.4 
CRC-NMSC 2.4 CRC-Endometrial 4.2 
Aerodigestive-NMSC 2.1 Bladder-CRC  3.8 
Breast-Haem B cell 2.1 CRC-Ovary 3 
NMSC – Non-melanoma skin cancer 
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Chapter 4 - Discussion 
 
Section 1 - Clinical Genetics series and population MPMT figures 
 
The clinical features of a series of multiple primary malignant tumour (MPMT) 
patients referred to a regional (West Midlands) clinical genetics service between 
the years of 1992 and 2012 were investigated. Half of the referrals that satisfied 
the inclusion criteria were referred in the last seven years of the twenty-year 
period. This may suggest an increasing awareness among non-genetic health care 
professionals of the relevance of inherited cancer syndromes for MPMT patients. It 
was discussed above that 16.8 cases per year might be expected to occur in the 
West Midlands population by chance alone if non-melanoma skin cancer (NMSC) 
is not considered. Discounting NMSC, the last 7 years of referral in our series 
produced 12.6 cases per year but not all MPMT patients will be referred for 
genetic assessment.  
 
These investigations complement previous epidemiological studies that have 
made clinical observations of MPMT patients at a population level. A series based 
on cancer registry data from the USA based Surveillance Epidemiology and End 
Results (SEER) programme collected between 1975 and 2001 identified 742,959 
(54% female) individuals who had been diagnosed with two cancers. 557,685 
(75.1%) patients had developed tumours at different sites and only 10.1% of these 
cases had both cancers diagnosed before the age of 60 years. The relative 
frequency of first cancer types is quoted in the study and among this group, the 
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most common first cancers were breast (19.7%), lymphoma (11.6%), female 
genital tract (10.9%), melanoma (9.5%) and colorectal (6.8%)65. The high 
proportion of lymphoma cases may, in part, be accounted for by carcinogenic 
treatments for this condition, in particular the risk of breast cancer post mantle 
radiotherapy in lymphoma cases diagnosed <30 years, which is known to be 
high84. Analysis of the most frequent first tumours observed in the West Midlands 
Clinical Genetics series (WM series) reveals a similar picture, albeit with higher 
proportions of BRCA1/BRCA2 or Lynch syndrome associated cancers with breast 
tumours making up 32.5% of first diagnoses, female genital tract 18.9%, colorectal 
17% and melanoma 5.2%. 9% of first cancers were non-melanoma skin cancers 
but incidence of these was not quoted in the SEER data. There were no cases of 
lymphoma as a first diagnosis. Further evidence for a preferential pattern of MPMT 
cases referred to clinical cancer genetics could be the relatively low numbers of 
cases with lung (5 cases) or prostate cancers (3 cases), both common tumours. 
 
The most frequent tumours observed overall in the WM series, therefore, reflect 
both incidence in the general population and the Clinical Genetics referral based 
nature of the patients. Breast, ovarian and colorectal cancer referrals make up 
over 90% of cancer genetic referrals to regional genetics services in the UK110 with 
a figure of 82.2% in a similar analysis of French services139. In both reports, breast 
and bowel cancer accounted for around 60% and 20% of referrals respectively. 
Breast, colorectal and NMSC were among the five most frequent tumours in the 
WM series, an observation that is also seen in the UK population129. Genetic 
cancer predisposition is often suggested by rarer tumours but assessment of 
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population attributable fraction (PAF) shows relatively low figures for many of the 
most frequent tumours in the series including breast (26.8%), colorectal (54.4%), 
ovarian (20.7%) and uterine (36.9%)22. The remaining proportion would include 
known cancer predisposition syndromes, other environmental exposures and as 
yet unidentified genetic factors. Chemo/radiotherapy related cancers are also likely 
to account for a number of cases though information regarding treatment of 
cancers in the series was generally not recorded in the clinical records analysed.   
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Section 2 – Assessing the evidence for unidentified cancer predisposing 
mutations in undiagnosed patients referred to Clinical Genetics services 
 
Comparison of most frequent tumours between those MPMT cases that were, and 
were not, found to harbour a constitutional mutation (Test+ve and Test-ve groups 
respectively) revealed broadly similar patterns for cancer subtypes (the five most 
common tumours in each group were similar). However, a higher proportion of 
breast cancers was observed in the Test-ve group, likely reflecting the fact that 
colorectal cases that would have gone on to test negative are likely to be excluded 
from germline genetic testing following microsatellite instability (MSI)/ 
immunohistochemistry (IHC) tumour analysis. 
 
The clinical evidence for underlying mutations in cancer predisposition genes 
(CPGs) was assessed in those individuals not demonstrated to have such a 
mutation by service based investigation. While, on average, clinical comparison 
between Test+ve and Test-ve groups revealed a lower age at diagnosis, higher 
multiple tumour score (MTS) and more familial (1st degree relative affected) cases 
in the Test+ve group, the analysis also revealed a significant number of Test-ve 
individuals with clinical indicators equally or more indicative of a constitutional 
mutation than many of the Test+ve group cases. This was also the case if all 
individuals without a demonstrable mutation were analysed, including those who 
had not had any genetic testing performed. This suggests that there may be an 
appreciable, as yet unidentified mutation burden in these individuals. 
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A significant limitation of the MTS was that it did not consider the contribution of 
environmental exposures to tumourigenesis. Some strongly associated cancers 
have comparatively high incidence rates at younger ages (e.g. cervical cancers) 
and could be scored relatively highly, as could rare cancers caused by 
environmental factors. Although the exposure information was generally not 
available from the clinical records analysed, PAF figures can give a guide as to 
probability of a cancer being due to environmental causes. PAF is imperfect as it 
only considers a certain number of known exposures but is still likely to be of 
assistance in identifying MPMT individuals more likely to be due to genetic 
predisposition. With this in mind this assessment was incorporated in later analysis 
of MPMT cases ascertained from a regional cancer registry.  
 
Additional analysis revealed that individuals with a higher MTS were more likely to 
have an elevated Manchester score or fulfill Revised Bethesda criteria. These are 
validated tools to predict mutation likelihood implying that MTS is also likely to be 
higher in patients harbouring a mutation predisposing to tumour development. This 
in turn suggests that the development of validated scores along similar lines 
incorporating all tumours may be useful in the assessment of individuals referred 
to cancer genetics and that further genotyping might be particularly likely to reveal 
mutations in cases within our series with an MTS at the higher end of the range. 
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Section 3 - Candidate gene analysis 
 
Although many individuals in the Test-ve group had cancers that are associated 
with PTEN or TP53 constitutional mutations, none were detected in the tested 
cases. Previous studies have assessed the frequency of mutations in these genes 
within an MPMT cohort. Shiseki et al found a TP53 mutation in one out of five 
patients diagnosed with three primary cancers, though that individual did conform 
to the Li-Fraumeni syndrome (LFS) phenotype according to classical diagnostic 
criteria140. Analysis of TP53 in 59 cases diagnosed with a second primary cancer 
revealed four mutation carriers141. None of those individuals fulfilled diagnostic 
criteria for LFS though all met the Chompret criteria for TP53 testing, which 
incorporates many of the core features of the classical criteria but is less 
stringent142. Only one case of 21 (5%) breast and sarcoma double primaries not 
fulfilling classical criteria for LFS was found to have a mutation in another study143. 
Deleterious TP53 mutations were also not identified in a series of 88 breast cancer 
cases with a personal or family history of MPMT144.  
 
De Vivo et al identified five individuals harbouring constitutional PTEN variants 
(V119L x 3 and V158L x 2) from a series of 103 MPMT cases drawn from a cohort 
of 32,826 nurses. There was no evidence of a diagnosis of Cowden syndrome 
among the variant carriers but all had been diagnosed with a tumour associated 
with that condition (breast and/or endometrial cancer). In-vitro functional studies of 
the identified variants via PTEN null cell line transfection assays suggested an 
increase in cell size and number145. The V119L variant is uncommon, involves a 
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conserved residue and is predicted as “probably pathogenic” on the basis of likely 
structural effect on the protein product by Polyphen2132 but no additional clinical 
information regarding carriers of either of these variants is available. It is therefore 
difficult to interpret these findings as evidence of PTEN mutations being significant 
within the context of an MPMT cohort. 
 
Testing of CDKN2B also revealed no firmly deleterious variants, though one case 
harboured a rare missense change in the gene where in-silico predictions were 
consistent with pathogenicity. However, the patient’s personal and family history 
did not contain occurrence of any tumours so far reported as associated with 
mutations in this gene and the variant is not found in publicly available databases 
relating genotype to disease phenotype. There is therefore insufficient evidence to 
assign this variant as significant in the aetiology of this patient’s cancers, 
particularly given that their tumours are common in the general population and 
could have occurred by chance. As CDKN2B becomes more established as a 
CPG both in research and clinical practice, it is likely that more robust information 
regarding associated tumour spectrum beyond renal cell carcinoma will become 
available along with a more comprehensive list of firmly pathogenic variants.   
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Section 4 –Possible reasons for non-detection of causative genetic changes 
in the MPMT series 
 
Although the findings of this study do not suggest that TP53, PTEN or CDKN2B 
should be widely analysed in MPMT cases referred to Clinical Genetics services 
as single gene tests, evidence was identified in favour of the hypothesis that many 
may harbour constitutional mutations in CPGs. Possible reasons for non-detection 
both in this study and by Clinical Genetics services fall into a number of 
categories.  
 
Novel genes and new phenotypic associations 
TP53 and PTEN are associated with multiple cancers and a broad tumour 
spectrum but are only two CPGs from a canon now numbering over 100. Recently 
identified genes associated with common tumours in the WM series such as 
POLD1, POLE (colorectal and endometrial cancers146) and POT1 (cutaneous 
melanoma14) were not available as a clinical test at the time of referral or included 
in our analysis and might explain some cases. It is also highly likely that a battery 
of novel CPGs is yet to be discovered. Many existing CPGs have well established 
associated phenotypes but the cancers associated with them may be amenable to 
revision due to previous ascertainment biases or inadequate time for the 
phenotype to be fully established. This study did not find any evidence to support 
the revision of the well-known phenotype associated with mutations in TP53, 
PTEN or expansion of the range of tumours caused by CDKN2B mutations. Other 
untested genes, however, that would not be expected to be causative based on 
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clinical assessment may account for further proportion of cases.   
 
Mosaicism 
Negative test results may result from somatic mosaicism for a mutation in a CPG, 
which is more likely in the absence of a family history of cancer. This phenomenon 
is well recognized as a cause of tumour predisposition that may evade detection 
by conventional genetic testing. Neurofibromatosis type 2 is a condition associated 
with various central nervous system tumours, particularly vestibular 
schwannomas. It is caused by mutations in the NF2 gene and mosaicism for a cell 
population containing them is estimated to account for around a third of cases147. 
Mosaicism has significant implications aside from influencing mutation detection in 
the laboratory. It can lead to attenuated phenotypes that may prevent further 
investigation for the condition in question and, when detected, is of reassurance to 
other family members as mosaic mutations occur post conception rather than 
being inherited (notwithstanding the small possibility of germline mosaicism where 
the cell population with the mutation is present in ovaries or testes and can be 
passed to offspring).  
 
The detection of mosaicism by blood sampling depends on cells carrying 
mutations making up at least a proportion of circulating nucleated cells. If this is 
the case, the probability of detecting them will be enhanced by a greater number 
of distinguishable molecular enquires in the analysed DNA sample for a given 
genomic coordinate of interest. Chromatogram peaks from Sanger sequencing (as 
performed by this study) present the relative proportions of base “calls” at a 
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particular position from the sequencing reaction products. They may reveal 
mosaicism but this is not reliable and is easy to interpret as an imperfect sequence 
readout. Next generation sequencing (NGS) techniques are often more sensitive 
in detecting low levels of mosaicism due to their ability to call a particular base 
hundreds of times in a sample, revealing mutations that are present in only a small 
proportion of cells from which DNA was extracted.  
 
Cell populations containing mutations in CPGs may not be represented in blood 
and present obvious difficulties with detection, even with next generation 
sequencing (NGS) techniques. More examples of this situation are emerging such 
as the finding of identical HIF2A mutations in a patient’s paraganglioma and 
somatostatinoma that explained both tumour’s formation. The mutation was not 
detected, however, in blood or other samples including urine, buccal cells and 
nails 148. In the not uncommon scenario where multiple tumours occur in the same 
patient66, it may be advantageous to perform genetic analysis on both tumours. 
The finding of a mutation common to both that is not present in blood would be 
reassuring for family members (as a hereditary condition becomes much less 
likely) and may guide treatment. Such analysis may become more widespread as 
NGS technologies are applied in surgical and oncological settings.    
 
Chromosome aberrations and exonic deletions/duplications 
More extensive constitutional genetic aberrations such as chromosomal 
abnormalities or whole exon deletions/duplications can predispose to tumour 
development. In the case of chromosome changes, a deletion can lead to an 
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individual possessing only one functional tumour suppressor allele. A duplication 
can affect the function of a tumour suppressor gene or increase the gene dosage 
of a proto-oncogene and translocation can also disrupt key genes. This study did 
not include karyotyping, which in any case can only detect larger rearrangements. 
Additionally, Sanger sequencing is not well suited to the detection of exonic 
deletions as the other corresponding allele still present in the sample is likely to 
generate a sequence readout indistinguishable from that generated by two alleles. 
Even NGS techniques such as multiple gene panel assays do not reliably detect 
chromosome abnormalities or whole exon deletion/duplications. Additional 
laboratory techniques such as multiplex ligation-dependent probe amplification 
(MLPA) are often required by diagnostic laboratories for detection of exonic 
deletions/duplications with karyotyping only performed in certain clinical scenarios 
where chromosome aberrations are more frequent (e.g. renal cell carcinoma). 
Tools exist for deletion/duplication detection from whole exome sequencing data 
though this is more difficult than where whole genome sequencing is used149. The 
latter technique also has the advantage of being able to detect and define 
translocation breakpoints as sequence readouts incorporating two genomic 
regions normally at distant chromosomal locations can be identified in the data.  
 
Epimutations 
The techniques used in this study analysed coding regions of the candidate genes 
only but CPGs that do not contain nucleotide variants in their coding sequence or 
regulatory regions may still be disrupted by epigenetic phenomena such as 
methylation that influences gene expression. This manner of disruption, termed 
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epimutation, is not detected by any of the methods discussed above and requires 
additional assays not routinely used in clinical laboratories. An example of a 
condition where epimutations are known to be relevant is Lynch syndrome, where 
deletions of EPCAM are causative in an estimated 1-3% of affected families150. A 
functional EPCAM gene product is not necessary for DNA mismatch repair but 
deletion of a 3’ section of this gene that normally acts to terminate transcription 
can lead to disruption of the adjacent promoter of MSH2 via continued 
transcription and consequent hypermethylation151. Assessment of the extent of 
epimutations in undiagnosed cancer predisposition syndromes will require further 
work that considers other factors in addition to a particular gene’s DNA sequence 
itself.  
 
Referral biases 
Many MPMT cases with genetic cancer predisposition may not be referred for 
assessment by clinical cancer genetics services. Such individuals would therefore 
not be considered for genetic testing or have been entered into this study. Patients 
with de novo mutations, for example, are less likely to have pronounced family 
histories of cancer and fulfill referral criteria. These criteria are also influenced by 
cancer types most firmly associated with recognised familial cancer syndromes 
and may prevent assessment of individuals with suggestive clinical parameters 
(e.g. young age of onset) but malignancies that do not correspond to a well-
established condition.  
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To begin to estimate what the MPMT burden due to constitutional genetic 
predisposition might be in the general population, data from a UK regional cancer 
registry covering a similar sized population to the West Midlands Regional 
Genetics Service was analysed. If cases occurring before the age of 60 are 
considered (as per the WM series), there were around 94 MPMT occurrences in 
the registry compared with 15 per year among West Midlands referrals. 
 
The most frequent tumours of each series were compared and it was found that 
cancers recorded in the registry generally reflected population incidence. Lung 
cancer, however, only made up 3% of cancers in older group, possibly explained 
by a poorer prognosis for this condition as a first cancer and consequent increased 
likelihood of dying before a second cancer is diagnosed. Haematological tumours 
of B-cell lineage were more frequent than their population incidence might 
suggest, perhaps reflecting the effects of previous cancer treatment in these 
individuals. The WM series reflected both population incidence and referral bias, 
containing an over representation of cancer combinations indicative of commonly 
investigated suspected inherited cancer syndromes such as Hereditary Breast and 
Ovarian Cancer and Lynch syndrome. 
 
To assess for evidence of constitutional genetic cancer predisposition in registry 
ascertained cases, tumour combinations in the series were observed. Around 22% 
of combinations occurred under the age of 50 years, an age at which such 
susceptibility is more likely. Designation of each tumour’s status based on 
population attributable fraction (PAF) and whether it was a common cancer was 
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used to further stratify this likelihood. It was shown that in ~35% of combinations in 
the under 50 age group, both tumours had a PAF <50% and in ~18% both were 
uncommon and had a PAF <50%. The latter figure was significantly higher in this 
age group compared to the older group.  
 
The registry data does not contain information relating to cancer therapies 
administered so it was not possible to assess how many combinations may have 
been due to treatment for the first cancer in a pairing. It also does not reveal how 
many cases were indeed referred for genetic assessment but numbers of cases 
and the nature of the tumour combinations observed suggest there may be a 
significant number of un-referred cases who harbour mutations in CPGs.  
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Section 5: Next generation sequencing in cancer genetics clinical practice 
 
Individuals with suspected cancer predisposition syndromes are generally referred 
to a clinical cancer genetics service for assessment. Such services have 
traditionally acted as gatekeepers to testing of the single gene that is most likely to 
explain the phenotype of the patient consulting their service (following extensive 
pre-test counselling relevant to that gene).  
 
This model has provided extensive information to patients and opportunities for 
risk management but has a number of limitations. Firstly, access to testing is 
restricted to those patients and families who conform to a phenotypic definition 
known to be characteristic of mutations in a given gene. This risks non-detection of 
significant mutations in patients whose cancers may not fit with the presumed 
typical phenotype and serves to maintain potentially inaccurate tumour estimates 
established due to ascertainment biases (see above). Secondly, sequential testing 
of candidate genes may be costly in terms of laboratory resources per patient and 
lead to a lengthy wait for results. Thirdly, the benefits of genetic testing rely on 
referral from a general practitioner or specialist, which may not always occur (even 
when referral criteria are fulfilled).  
 
In recent years, the development of NGS technologies have begun to challenge 
the standard model due to the possibility of lower cost, higher throughput analysis. 
Using these innovations to bring the initiation of testing more into the realm of the 
clinician dealing with the presenting problem (e.g. oncologist) is likely to help 
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address the above issues. NGS tests generate a far greater amount of data than 
traditional single gene tests and require extensive reference to clinical, 
bioinformatic and biological information for interpretation. An emerging role for the 
clinical cancer geneticist might be to translate those results into a clinical decision 
and to provide post-test counselling to guide a patient through their results. 
 
A methodology already in widespread use is that of the gene panel. In these 
assays, multiple genes potentially relevant to the patient's phenotype can be 
sequenced simultaneously. The number of genes on a panel may vary according 
to the number of genes associated with the relevant phenotype and the purposes 
of the laboratory using it.  
 
With analysis of increasing numbers of genes comes increasing probability of 
identifying variants of uncertain significance, which present difficulties to the 
clinician in advising patients and making management decisions. This is 
particularly true for most gene panels as variants in most or all of the genes 
analysed potentially explain the phenotype of the tested patient. Pre-test 
counselling for this possibility is an important consideration in the use of NGS 
applications for diagnostic purposes.  
 
Results generated from greater access to gene panel testing have the potential to 
reduce the biases resulting from testing criteria as more mutations are found in 
patients with phenotypes previously considered uncharacteristic for the gene in 
question. They increase the knowledge base pertaining to the effects of mutations 
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in CPGs, particularly true if clinical and variant information from these often rare 
cases is shared among clinicians and researchers through public databases.  
 
However, panel testing still restricts the number of genes analysed based on those 
most likely to be mutated in the phenotype that the panel was designed for. 
Mutations in genes hitherto thought to be unrelated will therefore not be detected 
through this method. The likelihood of this reduces as the number of tested genes 
increases and some panels aim to comprehensively cover nearly all known CPGs. 
A yet more agnostic approach is that of whole exome sequencing (WES), which 
aims to provide coverage of all coding regions of the genome through selective 
amplification and capture of those areas prior to sequencing. Data relating to 
candidate genes can be selectively analysed in a “virtual panel” technique with the 
remainder stored for future interrogation should new candidates come to light. 
Alternatively, all genes can be analysed using bioinformatic and experimental 
techniques to identify likely causative variants. The latter approach is largely 
restricted to research studies. Whole genome sequencing (WGS), also largely 
used in an academic setting, does not rely on selective amplification and capture 
and generates sequence from all coding and non-coding regions. This can 
produce better coverage of coding regions than WES and has the additional 
advantages of detecting chromosomal translocations and non-coding variants that 
may be significant. A further result of WES and WGS is the potential to produce 
incidental findings i.e. variants potentially affecting health in ways that did not 
prompt the test e.g. carrier status for a recessive condition. These may be 
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desirable for patients and families to receive but should receive attention in 
counselling procedures prior to these assays.  
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Appendices 
 
Appendix 1 – West Midlands MPMT series subgroups (cervical cancers 
excluded) 
5 most common 
tumour types 
All tumours  
(n=423) 
Testing sent 
(n=224) 
No testing 
sent (n=199) 
Test+ve 
group 
(n=88) 
Test-ve 
group  
(n=136) 
Breast 122 (28.8%) 65 (27.7%) 57 (28.6%) 18 (20.4%) 47 (34.5%) 
Ovarian 54 (12.8%) 35 (15.6%) 18 (9%) 14 (15.9%) 21 (15.4%) 
Colorectal  69 (16.3%) 33 (14.7%) 36 (18.1%) 20 (22.7%) 13 (9.5%) 
Endometrial 43 (10.2%) 28 (12.5%) 16 (8%) 12 (13.6%) 16 (11.8%) 
Non Melanoma Skin 41 (9.7%) 22 (9.8%) 21 (10.5%) 7 (7.9%) 15 (11%) 
Other tumours 
comprising < 5% total 
94 (22.2%) 41 (18.3%) 51 (25.6%) 17 (19.3%) 24 (17.6%) 
NMSC – Non melanoma skin cancer 
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Appendix 2 – West Midland MPMT series clinical analysis (cervical cancers 
excluded) 
 
All cases 
(n=203) 
Mutation 
identified 
(Test+ve) 
(n=40) 
No mutation 
identified. ≥ 1 
germ-line test 
(Test-ve) (n=66) 
No mutation 
identified 
(n=163) 
Mean age at tumour diagnosis 46.4 SD 10.1 44.2 SD 11 
46.1 (SD 9.8  
p=0.3692) 
47 (SD 9.8  
p=0.1408) 
Mean age diagnosis 1st tumour 42.7 SD 11.4  39.3 SD 13  
 42.8 (SD 10.2  
p=0.1462 ) 
43.5 (SD 10.8 
p=0.0588) 
Mean age diagnosis 2nd or 
synchronous tumour 
49.7 SD 7.2 
48.1 SD 
6.7  
49.2( SD 8.2  
p=0.4522) 
50.1 (SD 7.3 
p=0.0966) 
Mean individual age at tumour 
diagnosis 
46.4 SD 8.4 
44.4 SD 
8.8  
46.1 (SD 8.6  
p=0.3309 ) 
47 (SD 8.2 
p=0.0898) 
% cases with individual mean 
age at tumour diagnosis ≤ 
Test+ve group median (= 46.6 ) 
N/A N/A 42.4% (38) 
39.2% (64) 
 
% cases with concordant 
tumour in 1st degree relative 
52.2% (106) 65% (26) 
57.6% (38) 
p=0.4473 
49% (80) 
p=0.0703 
Mean multiple tumour score 14.7 SD 8.9 
21.6 SD 
14.6 
14.2 (SD 5.4  
p =0.0021) 
13 (SD 5.6  
p=0.0003) 
% cases with multiple tumour 
score ≥ Test+ve group median 
(=16.5) 
N/A N/A 
28.8% (19) 
 
21.5% (35) 
Mean individual age at diagnosis = Combined age of tumours ÷ number of tumours in individual. P 
values describe two tailed comparison with Test+ve group (H0 = µ1 = µ2). 
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Appendix 3 – Tumour subgroups observed in National Cancer Registration 
Service – Eastern Office series 
 
≥2 tumours under 50 ≥2 tumours not until after 50 
Cancer type 
No. cases. 
% total in 
brackets 
Cancer type 
No. cases. % 
total in brackets 
Non-melanoma skin  60 (20.7) Non-melanoma skin  222 (24.6) 
Breast 52  (18.0) Breast  130 (14.4) 
Melanoma 38  (13.1) Haematological (B-cell)  75 (8.3) 
Haematological (B-cell) 17  (5.9) Melanoma  73 (8.1) 
Colorectal 12  (4.1) Prostate  72 (8) 
Endometrium 10  (3.4) Colorectal  57 (6.3) 
Thyroid 10  (3.4) Endometrium  39 (4.3) 
Aerodigestive tract 8  (2.8) Aerodigestive tract 34 (3.8) 
Sarcoma 8  (2.8) Lung  27 (3) 
Cervix 7  (2.4) Ovary  25 (2.8) 
Central nervous system 7  (2.4) Kidney  18 (2) 
Bladder 6  (2.1) Thyroid  18 (2) 
Ovary 6  (2.1) Bladder  16 (1.8) 
Prostate 6  (2.1) Testis  13 (1.4) 
Testis   6  (2.1) Neuroendocrine 12 (1.3) 
Kidney 5  (1.7) Haematological (T-cell)  8 (0.9) 
Haematological 
(Lymphoblastic) 
4  (1.4) Cervix  7 (0.8) 
Haematological (Myeloid) 4  (1.4) Sarcoma  7 (0.8) 
Salivary gland 4  (1.4) Gastric  6 (0.7) 
Haematological (T-cell) 3  (1.0) Salivary gland  6 (0.7) 
Neuroendocrine 3  (1.0) Anus  5 (0.5) 
Adrenal 2  (0.7) 
Haematological 
(Myeloid)  
4 (0.4) 
Haematological ( Mast cell) 2  (0.7) Eye  3 (0.3) 
Lung   2  (0.7) Skin (other)  3 (0.3) 
Biliary 1  (0.3) Biliary  2 (0.2) 
Gastric 1  (0.3) Mesothelioma  2 (0.2) 
Mediastinum 1  (0.3) Oesophagus  2 (0.2) 
Oesophagus 1  (0.3) Penis  2 (0.2) 
Skin (other) 1  (0.3) Small bowel  2 (0.2) 
Ureter 1  (0.3) Thymus  2 (0.2) 
Uterus   1  (0.3) Ureter  2 (0.2) 
Vulva   1  (0.3) Vulva  2 (0.2) 
  Central nervous system  1 (0.1) 
  Liver  1 (0.1) 
  Odontogenic  1 (0.1) 
  Pancreas  1 (0.1) 
  Parathyroid  1 (0.1) 
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